<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults - Gbabe, OF - 2014 | Cochrane Library</title> <meta content="Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults - Gbabe, OF - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003256.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults - Gbabe, OF - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003256.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003256.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults" name="citation_title"/> <meta content="Oluwatoyin F Gbabe" name="citation_author"/> <meta content="Stellenbosch University" name="citation_author_institution"/> <meta content="gbabetoyin@yahoo.com" name="citation_author_email"/> <meta content="Charles I Okwundu" name="citation_author"/> <meta content="Martin Dedicoat" name="citation_author"/> <meta content="Birmingham Heartlands Hospital" name="citation_author_institution"/> <meta content="Esther E Freeman" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD003256.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/09/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003256.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003256.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003256.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antiretroviral Therapy, Highly Active; Alitretinoin; Antineoplastic Agents [*therapeutic use]; Bleomycin [administration &amp; dosage]; Doxorubicin [administration &amp; dosage]; Drug Therapy, Combination; Etoposide [administration &amp; dosage]; HIV Infections [*complications, drug therapy]; Liposomes; Observational Studies as Topic; Randomized Controlled Trials as Topic; Sarcoma, Kaposi [*drug therapy, virology]; Skin Neoplasms [*drug therapy, virology]; Tretinoin [therapeutic use]; Vincristine [administration &amp; dosage]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003256.pub2&amp;doi=10.1002/14651858.CD003256.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003256\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003256\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003256.pub2",title:"Treatment of severe or progressive Kaposi\u0027s sarcoma in HIV\\u2010infected adults",firstPublishedDate:"Sep 1, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane HIV/AIDS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003256.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003256.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003256.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003256.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003256.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003256.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003256.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003256.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003256.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003256.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3298 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003256.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-sec-0111"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-sec-0020"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-sec-0021"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-sec-0049"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-sec-0105"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/appendices#CD003256-sec-0116"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/table_n/CD003256StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/table_n/CD003256StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/information#CD003256-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Oluwatoyin F Gbabe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/information#CD003256-cr-0003">Charles I Okwundu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/information#CD003256-cr-0004">Martin Dedicoat</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003256.pub2/information#CD003256-cr-0005">Esther E Freeman</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/information/en#CD003256-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 September 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003256.pub2">https://doi.org/10.1002/14651858.CD003256.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003256-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003256-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003256-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003256-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003256-abs-0001" lang="en"> <section id="CD003256-sec-0001"> <h3 class="title" id="CD003256-sec-0001">Background</h3> <p>Kaposi's sarcoma remains the most common cancer in Sub‐Saharan Africa and the second most common cancer in HIV‐infected patients worldwide. Since the introduction of highly active antiretroviral therapy (HAART), there has been a decline in its incidence. However, Kaposi's sarcoma continues to be diagnosed in HIV‐infected patients. </p> </section> <section id="CD003256-sec-0002"> <h3 class="title" id="CD003256-sec-0002">Objectives</h3> <p>To assess the added advantage of chemotherapy plus HAART compared to HAART alone; and the advantages of different chemotherapy regimens in HAART and HAART naive HIV infected adults with severe or progressive Kaposi's sarcoma. </p> </section> <section id="CD003256-sec-0003"> <h3 class="title" id="CD003256-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE and , GATEWAY, the WHO Clinical Trials Registry Platform and the US National Institutes of Health's ClinicalTrials.gov for ongoing trials and the Aegis archive of HIV/AIDS for conference abstracts. An updated search was conducted in July 2014. </p> </section> <section id="CD003256-sec-0004"> <h3 class="title" id="CD003256-sec-0004">Selection criteria</h3> <p>Randomised trials and observational studies evaluating the effects of any chemotherapeutic regimen in combination with HAART compared to HAART alone, chemotherapy versus HAART, and comparisons between different chemotherapy regimens. </p> </section> <section id="CD003256-sec-0005"> <h3 class="title" id="CD003256-sec-0005">Data collection and analysis</h3> <p>Two review authors assessed the studies independently and extracted outcome data. We used the risk ratio (RR) with a 95% confidence interval (CI) as the measure of effect. We did not conduct meta‐analysis as none of the included trials assessed identical chemotherapy regimens. </p> </section> <section id="CD003256-sec-0006"> <h3 class="title" id="CD003256-sec-0006">Main results</h3> <p>We included six randomised trials and three observational studies involving 792 HIV‐infected adults with severe Kaposi's sarcoma. Seven studies included patients with a mix of mild to moderate (T0) and severe (T1) Kaposi's sarcoma. However, this review was restricted to the subset of participants with severe Kaposi's sarcoma disease. </p> <p>Studies comparing HAART plus chemotherapy to HAART alone showed the following: one trial comparing HAART plus doxorubicin, bleomycin and vincristine (ABV) to HAART alone showed a significant reduction in disease progression in the HAART plus ABV group (RR 0.10; 95% CI 0.01 to 0.75, 100 participants); there was no statistically significant reduction in mortality and no difference in adverse events. A cohort study comparing liposomal anthracyclines plus HAART to HAART alone showed a non‐statistically significant reduction in Kaposi's sarcoma immune reconstitution inflammatory syndrome in patients that received HAART plus liposomal anthracyclines (RR 0.49; 95% CI 0.16 to 1.55, 129 participants). </p> <p>Studies comparing HAART plus chemotherapy to HAART plus a different chemotherapy regimen showed the following: one trial involving 49 participants and comparing paclitaxel versus pegylated liposomal doxorubicin in patients on HAART showed no difference in disease progression. Another trial involving 46 patients and comparing pegylated liposomal doxorubicin versus liposomal daunorubicin showed no participants with progressive Kaposi's sarcoma disease in either group. </p> <p>Studies comparing different chemotherapy regimens in patients from the pre‐HAART era showed the following: in the single RCT comparing liposomal daunorubicin to ABV, there was no significant difference with the use of liposomal daunorubicin compared to ABV in disease progression (RR 0.78; 95% CI 0.34 to 1.82, 227 participants) and overall response rate. Another trial involving 178 participants and comparing oral etoposide versus ABV demonstrated no difference in mortality in either group. A non‐randomised trial comparing bleomycin alone to ABV demonstrated a higher median survival time in the ABV group; there was also a non‐statistically significant reduction in adverse events and disease progression in the ABV group (RR 11; 95% CI 0.67 to 179.29, 24 participants). An additional non‐randomised study showed a non‐statistically significant overall mortality benefit from liposomal doxorubicin as compared to conservative management consisting of either bleomycin plus vinblastine, vincristine or single‐agent antiretroviral therapy alone (RR 0.93; 95% CI 0.75 to 1.15, 29 participants). The overall quality of evidence can be described as moderate quality. The quality of evidence was downgraded due to the small size of many of the included studies and small number of events. </p> </section> <section id="CD003256-sec-0007"> <h3 class="title" id="CD003256-sec-0007">Authors' conclusions</h3> <p>The findings from this review suggest that HAART plus chemotherapy may be beneficial in reducing disease progression compared to HAART alone in patients with severe or progressive Kaposi's sarcoma. For patients on HAART, when choosing from different chemotherapy regimens, there was no observed difference between liposomal doxorubicin, liposomal daunorubicin and paclitaxel. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003256-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003256-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003256-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003256-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003256-abs-0004">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003256-abs-0003" lang="en"> <h3>Treatment of severe or progressive Kaposi's sarcoma in HIV‐infected adults</h3> <p>Kaposi’s sarcoma was the first tumor to be described in association with HIV infection and is an AIDS‐defining condition. It is also known as Kaposi's sarcoma‐associated herpes virus (KSHV) as Herpes virus 8 (HHV8) is recognized as an essential and necessary factor in the pathogenesis of KS. Nonetheless, not all HHV‐8‐infected individuals will develop the disease. The abnormal cells of KS form purple, red, or brown patches, plaques or tumors on the skin. There is no universally accepted system for staging Kaposi's sarcoma. The most commonly used staging system for AIDS‐related KS in adults is the AIDS Clinical Trial Group (ACTG) staging. </p> <p>This review evaluated the effects of highly active antiretroviral therapy (HAART) and chemotherapy, or different chemotherapy regimens for severe or progressive Kaposi's sarcoma in HIV infected adults. </p> <p>We found six randomised controlled trials and three observational studies that assessed the effects of HAART plus chemotherapy compared with HAART alone; HAART plus chemotherapy compared with HAART plus another chemotherapy regimen; and chemotherapy compared with chemotherapy in the time before HAART was available. Of the nine included studies, seven included patients with a mix of mild to moderate (T0) Kaposi's sarcoma and severe (T1) Kaposi's sarcoma. There was no universal definition for what severity of disease was considered chemotherapy‐requiring. For this review, we only extracted data for 792 HIV infected adults with severe Kaposi's sarcoma disease. </p> <p>The findings from this review suggest that HAART plus chemotherapy may be beneficial in reducing disease progression compared to HAART alone in patients with severe or progressive Kaposi's sarcoma. For patients on HAART, in choosing among different chemotherapy regimens, there was no observed difference between liposomal doxorubcin, liposomal daunorubicin, and paclitaxel. The overall quality of evidence in this review can be described as moderate. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003256-sec-0111" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003256-sec-0111"></div> <h3 class="title" id="CD003256-sec-0112">Implications for practice</h3> <section id="CD003256-sec-0112"> <p>The findings from this review suggest that highly active antiretroviral therapy (HAART) plus chemotherapy may be beneficial in reducing disease progression compared to HAART alone in patients with severe or progressive Kaposi's sarcoma. For patients on HAART, when choosing from different chemotherapy regimens, there was no observed difference between liposomal doxorubicin, liposomal daunorubicin and paclitaxel. </p> </section> <h3 class="title" id="CD003256-sec-0113">Implications for research</h3> <section id="CD003256-sec-0113"> <p>Future studies should be designed and powered specifically to address outcomes for patients with severe or progressive Kaposi's sarcoma and the results should be presented according to disease severity. The delineation of what severity of disease truly needs chemotherapy in addition to HAART, and who may be treated with HAART alone, has yet to be firmly established. While this review demonstrates that there is at least a treatment response advantage to adding chemotherapy to HAART in patients with T1 disease, this does not necessarily mean that ACTG tumour staging is the most appropriate cut‐off for clinicians to use when deciding who to treat with chemotherapy. For example, there may be subgroups of T1 patients that could be treated with HAART alone, or subgroups within T0 that require immediate anti‐KS therapy. The studies included in this review were not powered in such a way to allow us to perform sub‐group analyses. There is also a need for research on the relative timing of HAART in relation to chemotherapy for severe Kaposi's sarcoma, and the potential role of chemotherapy in preventing or treating Kaposi's sarcoma immune reconstitution inflammatory syndrome. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003256-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003256-sec-0015"></div> <div class="table" id="CD003256-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HAART + ABV compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HAART + ABV compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> Durban, South Africa<br/> <b>Intervention:</b> HAART + ABV<br/> <b>Comparison:</b> HAART alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + ABV</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> <br/> (108 to 451) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> <br/> (0.45 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progressive disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (2 to 150) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.1</b> <br/> (0.01 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> <br/> (51 to 498) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2</b> <br/> (0.64 to 6.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ partial response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>479 per 1000</b> <br/> (283 to 815) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b> <br/> (1.01 to 2.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ stable disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (0 to 158) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.06</b> <br/> (0 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ overall response (complete and partial)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>641 per 1000</b> <br/> (418 to 979) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b> <br/> (1.16 to 2.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>520 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> <br/> (307 to 686) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/> (0.59 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ABV:</b> doxorubicin, bleomycin and vincristine; <b>CI:</b> confidence interval; <b>HAART:</b> highly active antiretroviral therapy; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003256-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">HAART + pegylated liposomal doxorubicin compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HAART + pegylated liposomal doxorubicin compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> Spain<br/> <b>Intervention:</b> HAART + PLD<br/> <b>Comparison:</b> HAART alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + PLD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 9</b> <br/> (0.61 to 133.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>HAART:</b> highly active antiretroviral therapy; <b>PLD:</b> pegylated liposomal doxorubicin; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003256-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">HAART + liposomal anthracycline compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HAART + liposomal anthracycline compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a><b>) ‐ cohort study</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> United Kingdom<br/> <b>Intervention:</b> HAART + liposomal anthracycline<br/> <b>Comparison:</b> HAART alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + liposomal anthracycline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/> (22 to 274) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> <br/> (0.35 to 4.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kaposi's sarcoma IRIS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> <br/> (20 to 194) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b> <br/> (0.16 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IRIS:</b> immune reconstitution inflammatory syndrome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003256-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">HAART + paclitaxel compared to HAART + pegylated liposomal doxorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HAART + paclitaxel compared to HAART + PLD for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> USA<br/> <b>Intervention:</b> HAART + paclitaxel<br/> <b>Comparison:</b> HAART + PLD </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + PLD</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + paclitaxel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression of Kaposi's sarcoma</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> <br/> (3 to 629) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/> (0.07 to 15.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> <br/> (8 to 860) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.08</b> <br/> (0.2 to 21.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ partial response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b> <br/> (180 to 781) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/> (0.5 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ stable disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>248 per 1000</b> <br/> (108 to 580) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b> <br/> (0.27 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>HAART:</b> highly active antiretroviral therapy; <b>PLD:</b> pegylated liposomal doxorubicin; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003256-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">HAART + pegylated liposomal doxorubicin compared to HAART + liposomal daunorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HAART + pegylated liposomal doxorubicin compared to HAART + liposomal daunorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> USA<br/> <b>Intervention:</b> HAART + pegylated liposomal doxorubicin<br/> <b>Comparison:</b> HAART + liposomal daunorubicin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + liposomal daunorubicin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + PLD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression of Kaposi's sarcoma</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>HAART:</b> highly active antiretroviral therapy; <b>PLD:</b> pegylated liposomal doxorubicin; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003256-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Liposomal daunorubicin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Liposomal daunorubicin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> USA<br/> <b>Intervention:</b> liposomal daunorubicin<br/> <b>Comparison:</b> ABV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ABV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Liposomal daunorubicin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression of Kaposi's sarcoma</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>99 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/> (34 to 180) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> <br/> (0.34 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> <br/> (3 to 245) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.87</b> <br/> (0.3 to 27.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ partial response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b> <br/> (143 to 354) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> <br/> (0.53 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ overall response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>279 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b> <br/> (162 to 385) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.9</b> <br/> (0.58 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ stable disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>577 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> <br/> (502 to 767) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.87 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>964 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>974 per 1000</b> <br/> (925 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/> (0.96 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ABV:</b> doxorubicin, bleomycin and vincristine; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003256-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Oral etoposide compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral etoposide compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> Zimbabwe<br/> <b>Intervention:</b> oral etoposide<br/> <b>Comparison:</b> ABV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ABV </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oral etoposide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>864 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>933 per 1000</b> <br/> (846 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.98 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ABV:</b> doxorubicin, bleomycin and vincristine; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were few events with wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003256-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Bleomycin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bleomycin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a><b>) ‐ non‐RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> Venezuela<br/> <b>Intervention:</b> bleomycin<br/> <b>Comparison:</b> ABV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ABV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Bleomycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>917 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>999 per 1000</b> <br/> (797 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b> <br/> (0.87 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ partial response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> <br/> (3 to 620) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.11</b> <br/> (0.01 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ stable disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>587 per 1000</b> <br/> (313 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/> (0.47 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ progression</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 11</b> <br/> (0.67 to 179.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 11</b> <br/> (0.67 to 179.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ABV:</b> doxorubicin, bleomycin and vincristine; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003256-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Liposomal doxorubicin compared to conservative management for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Liposomal doxorubicin compared to bleomycin + vinblastine, vincristine or single‐agent antiretroviral therapy alone (conservative management) for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a><b>) ‐ non‐RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> Germany<br/> <b>Intervention:</b> liposomal doxorubicin<br/> <b>Comparison:</b> conservative management </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Liposomal doxorubicin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Conservative management</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>930 per 1000</b> <br/> (750 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b> <br/> (0.75 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003256-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003256-sec-0016"></div> <p>Acquired immunodeficiency syndrome (AIDS)‐defining cancers, including Kaposi's sarcoma, have become common comorbidities afflicting HIV‐infected individuals (<a href="./references#CD003256-bbs2-0055" title="CasperC . The increasing burden of HIV‐associated malignancies in resource‐limited regions. Annual Review of Medicine2011;62:157‐70. ">Casper 2011</a>). Kaposi's sarcoma was the first tumour to be described in association with HIV infection and is an AIDS‐defining condition. Kaposi's sarcoma remains the most common HIV‐associated cancer in Sub‐Saharan Africa and the second most common cancer in HIV‐infected patients worldwide (<a href="./references#CD003256-bbs2-0063" title="GanttS , KakuruA , WaldA , WalusansaV , CoreyL , CasperC , et al. Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children. Pediatric Blood Cancer2010;54(5):670‐4. ">Gantt 2010</a>). Since the introduction of 'highly active antiretroviral therapy' (HAART) or combination antiretroviral therapy (cART), there has been a rapid decline in the incidence of Kaposi's sarcoma, especially in Western countries where HAART is readily available (<a href="./references#CD003256-bbs2-0059" title="DiLorenzoG , KonstantinopoulosPA , PantanowitzL , DiTrolioR , DePlacidoS , DezubeBJ . Management of AIDS‐related Kaposi's sarcoma. The Lancet Oncology2007;8(2):167‐76. ">Di Lorenzo  2007</a>; <a href="./references#CD003256-bbs2-0066" title="JonesJL , HansonDL , DworkinMS , JaffeHW . Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. Journal of Acquired Immune Deficiency Syndrome2000;24:270‐4. ">Jones 2000</a>; <a href="./references#CD003256-bbs2-0073" title="MocroftA , KirkO , ClumeckN , Gargalianos‐KakolyrisP , TrochaH , ChentsovaN , et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003: the EuroSIDA Study. Cancer2004;100:2644–54. ">Mocroft 2004</a>). The reduction in incidence of Kaposi's sarcoma is less clear in resource poor settings (<a href="./references#CD003256-bbs2-0074" title="SemeereAS , BusakhalaN , MartinJN . Impact of Antiretroviral Therapy on the Incidence of Kaposi’s Sarcoma in Resource‐rich and Resource‐limited Settings. Current opinion in oncology2012;24(5):522‐530. ">Semeere 2012</a>). However, it continues to be diagnosed in HIV‐infected patients, even among patients with effective viral load suppression and high CD4 counts (<a href="./references#CD003256-bbs2-0067" title="KhanlouH , SteinT , FarthingC . Development of Kaposi sarcoma despite sustained suppression of HIV plasma viremia. Journal of Acquired Immune Deficiency Syndrome2000;23(4):361. ">Khanlou 2000</a>; <a href="./references#CD003256-bbs2-0072" title="MaurerT , PonteM , LeslieK . HIV‐Associated Kaposi's Sarcoma with a High CD4 Count and a Low Viral Load. New England Journal of Medicine2007;357:1352‐1353. ">Maurer 2007</a>). Survival after a diagnosis of KS in the modern HAART era continues to be sub‐optimal in resource poor settings (<a href="./references#CD003256-bbs2-0062" title="FreemanE , SemeereA , WengerM , MwebesaB , AsirwaFC , BusakhalaN , et al. Pitfalls of Practicing Cancer Epidemiology in resource‐limited settings: The case of survival after a diagnosis with Kaposi’s sarcoma in sub‐Saharan Africa. 14th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies. November 2013. ">Freeman 2013</a>). Together, incident cases and poor survival in some settings emphasises the importance of understanding the treatment options for severe or progressive Kaposi's sarcoma.  </p> <section id="CD003256-sec-0017"> <h3 class="title" id="CD003256-sec-0017">Description of the condition</h3> <p>Kaposi's sarcoma is thought to originate from herpes virus 8 (HHV8)‐infected lymphatic endothelial cells and is also known as Kaposi's sarcoma‐associated herpes virus (KSHV). HHV8 is recognised as an essential and necessary factor in the pathogenesis of Kaposi's sarcoma (<a href="./references#CD003256-bbs2-0053" title="BrowningPJ ,  SechlerJM ,  KaplanM ,  WashingtonRH ,  GendelmanR ,  YarchoanR ,  etal . Identification and culture of Kaposi’s sarcoma‐like spindle cells from the peripheral blood of human immunodeficiency virus‐1‐infected individuals and normal controls. Blood1994;84:2711‐20. ">Browning 1994</a>; <a href="./references#CD003256-bbs2-0056" title="ChangY , CesarmanE , PessinM , LeeF , CulpepperJ , KnowlesDM , et al. Identification of new human herpesvirus‐like DNA sequences in AIDS‐associated Kaposi's sarcoma. Science1994;266(5192):1865‐9. ">Chang 1994</a>; <a href="./references#CD003256-bbs2-0058" title="DavisMA ,  StürzlMA ,  BlasigC ,  SchreierA ,  GuoHG ,  ReitzM , et al. Expression of human herpesvirus 8‐encoded cyclin D in Kaposi’s sarcoma spindle cells. Journal of the National Cancer Institute1997;89:1868‐74. ">Davis 1997</a>). Nonetheless, not all HHV‐8‐infected individuals will develop the disease. </p> <p>Kaposi's sarcoma lesions are comprised of both distinctive spindle cells that line lymph or blood vessels and a variable inflammatory infiltrate, suggesting that it may result from reactive hyperproliferation induced by chronic inflammation and is not a true neoplasm (<a href="./references#CD003256-bbs2-0070" title="MartellottaF , BerrettaM , VaccherE , SchioppaO , ZanetE , TirelliU . AIDS‐related Kaposi's sarcoma: state of the art and therapeutic strategies. Current HIV Research 2009;7(6):634‐8. ">Martellotta 2009</a>).The abnormal cells of Kaposi's sarcoma form purple or brown patches, plaques or tumours on the skin. Biopsy for definitive diagnosis is recommended to distinguish Kaposi's sarcoma from other skin conditions that can look similar, which may include bacillary angiomatosis, non‐Hodgkin lymphoma, and cutaneous fungal or bacterial infections (<a href="./references#CD003256-bbs2-0069" title="KrownSE . Clinical characteristics of Kaposi sarcoma. HIV InSite Knowledge Base ChapterFebruary 2006. ">Krown 2006</a>). </p> <p>There is no universally accepted system for staging AIDS‐related Kaposi's sarcoma. The most commonly used staging system for AIDS‐related Kaposi's sarcoma in adults was developed by the AIDS Clinical Trial Group (ACTG) of the National Institutes of Health (<a href="./references#CD003256-bbs2-0068" title="KrownSE , MetrokaC , WernzJC . Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. Journal of Clinical Oncology1989;7(9):1201‐7. ">Krown 1989</a>). It is important to note that this staging system is most frequently used in research. Clinically, patients may be grouped more generally by a clinician into either a) sick patients needing an immediate fast‐acting intervention (clinically severe Kaposi's sarcoma) or b) those patients that can be treated with HAART alone (clinically mild to moderate Kaposi's sarcoma). There is continued debate in the literature as to the definition of the severity of KS that is truly requiring of immediate fast‐acting intervention as compared to HAART alone, and different definitions have been used in different studies (<a href="./references#CD003256-bbs2-0071" title="MartinJ , Laker‐OkettaM , WalusanaV , OremJ , WabingaH , BennettJ , et al. Antiretrovirals for Kaposi’s Sarcoma (ARKS): A randomized trial of protease inhibitor‐based antiretroviral therapy for AIDS‐associated Kaposi’s sarcoma in sub‐Saharan Africa. 14th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies. November 2013. ">Martin 2013</a>). </p> <p>In ACTG staging, patients are categorised according to three parameters.</p> <p> <ul id="CD003256-list-0001"> <li> <p>Extent of tumour (T): a favourable prognosis (T0) is associated with disease limited to the skin or with minimal involvement of the oral cavity. Those with associated lymphoedema, more extensive oral cavity involvement or other visceral disease are considered to have a poor prognosis (T1). </p> </li> <li> <p>Immune status (I): the degree of immunosuppression from the HIV infection is an important prognostic factor. Patients with a CD4 count greater than 200 cells/µl are considered to have a favourable prognosis (I0), while those with a lower CD4 count are classified as having a poor prognosis (I1). </p> </li> <li> <p>Severity of systemic illness (S): features associated with a poor risk included the following (S1): a history of opportunistic infection, thrush, B symptoms (fever, night sweats, significant weight loss, diarrhoea for more than two weeks). Patients without any of these factors have a more favourable prognosis (S0). </p> </li> </ul> </p> </section> <section id="CD003256-sec-0018"> <h3 class="title" id="CD003256-sec-0018">Description of the intervention</h3> <p>HAART has been a very important step in the treatment of AIDS‐related Kaposi's sarcoma and has led to a substantial reduction in morbidity and mortality (<a href="./references#CD003256-bbs2-0052" title="BowerM ,  PalmieriC ,  DhillonT . AIDS‐related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Current Opinion in Infectious Diseases2006;19(1):14‐9. ">Bower 2006</a>; <a href="./references#CD003256-bbs2-0054" title="CarrieriMP ,  PradierC ,  PiselliP ,  PicheM ,  RosenthalE ,  HeudierP , et al. Reduced incidence of Kaposi's sarcoma and of systemic non‐Hodgkin's lymphoma in HIV‐infected individuals treated with highly active antiretroviral therapy. International Journal of Cancer2003;103(1):142‐4. ">Carrieri 2003</a>; <a href="./references#CD003256-bbs2-0059" title="DiLorenzoG , KonstantinopoulosPA , PantanowitzL , DiTrolioR , DePlacidoS , DezubeBJ . Management of AIDS‐related Kaposi's sarcoma. The Lancet Oncology2007;8(2):167‐76. ">Di Lorenzo  2007</a>; <a href="./references#CD003256-bbs2-0061" title="EngelsEA ,  PfeifferRM ,  GoedertJJ ,  VirgoP ,  McNeelTS ,  ScoppaSM , et al. Trends in cancer risk among people with AIDS in the United States 1980‐2002. AIDS2006;20(12):1645‐54. ">Engels 2006</a>; <a href="./references#CD003256-bbs2-0064" title="GrulichAE ,  LiY ,  McDonaldAM ,  CorrellPK ,  LawMG ,  KaldorJM . Decreasing rates of Kaposi's sarcoma and non‐Hodgkin's lymphoma in the era of potent combination anti‐retroviral therapy. AIDS2001;15(5):629‐33. ">Grulich 2001</a>). In addition to HAART, many other potential systemic and local therapeutic regimens exist, which have been studied in HIV‐infected adults. Generally, more widespread disease, or disease affecting internal organs, is treated with systemic therapy (including interferon alpha, liposomal anthracyclines or paclitaxel). Liposomal anthracyclines were found in the previous version of this Cochrane review to have a superior response rate without an increase in toxic side effects (<a href="./references#CD003256-bbs2-0075" title="DedicoatM , VaithilingumM , NewtonRR . Treatment of Kaposis sarcoma in HIV‐1 infected individuals with emphasis on resource poor settings. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD003256] ">Dedicoat 2003</a>), and have been adopted by many as first‐line therapy for severe Kaposi's sarcoma (<a href="./references#CD003256-bbs2-0060" title="DiTrolioR , DiLorenzoG , DelfinoM , DePlacidoS . Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review. International Journal of Immunopathology and Pharmacology2006;19(2):253‐63. ">Di Trolio 2006</a>). However, at this time there are no guidelines from the World Health Organization regarding liposomal anthracyclines as first‐line therapy and access to these drugs is still very limited in the developing world. Since the prior Cochrane review, more studies have been published in this area, necessitating an update of the literature. With the advent of ART, local treatment is often reserved for patients who do not respond to systemictherapy.                                        </p> </section> <section id="CD003256-sec-0019"> <h3 class="title" id="CD003256-sec-0019">Why it is important to do this review</h3> <p>The incidence of AIDS‐related Kaposi's sarcoma remains high in many countries where HIV‐1 is prevalent, especially in Sub‐Saharan Africa. This review aims to identify high‐quality studies of therapy for clinically severe or treatment‐refractory Kaposi's sarcoma. Studies using HAART plus chemotherapy or different chemotherapy regimens in both the pre‐ andpost‐HAART era will be included. The previous version of this review included HIV‐1‐infected adult patients with both mild and severe/progressive Kaposi's sarcoma (<a href="./references#CD003256-bbs2-0075" title="DedicoatM , VaithilingumM , NewtonRR . Treatment of Kaposis sarcoma in HIV‐1 infected individuals with emphasis on resource poor settings. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD003256] ">Dedicoat 2003</a>). However, this update of the review will be restricted to severe or progressive Kaposi's sarcoma. Another ongoing Cochrane systematic review will address treatment for mild and moderate Kaposi's sarcoma in ART‐naive HIV‐infected individuals. We aim to present the best available evidence from randomised controlled trials and observational studies. The findings from our review will help to guide policy and practice on the treatment of AIDS‐related Kaposi's sarcoma in adults with HIV infection. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003256-sec-0020" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003256-sec-0020"></div> <p>To assess the added advantage of chemotherapy plus HAART compared to HAART alone; and the advantages of different chemotherapy regimens in HAART and HAART naive HIV infected adults with severe or progressive Kaposi's sarcoma. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003256-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003256-sec-0021"></div> <section id="CD003256-sec-0022"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003256-sec-0023"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials and observational studies with a comparison group.</p> </section> <section id="CD003256-sec-0024"> <h4 class="title">Types of participants</h4> <p>HIV‐infected adults diagnosed with Kaposi's sarcoma, considered to have the following.</p> <p> <ul id="CD003256-list-0002"> <li> <p>Severe Kaposi's sarcoma, requiring anti‐Kaposi's sarcoma therapy, defined as patients with: </p> <ul id="CD003256-list-0003"> <li> <p>  ACTG T1 disease; or</p> </li> <li> <p>  where ACTG staging is not available or analysis by ACTG stage is unobtainable, defined as: </p> <ul id="CD003256-list-0004"> <li> <p>documented or clinically suspected pulmonary or gastrointestinal Kaposi's sarcoma;</p> </li> <li> <p>oral Kaposi's sarcoma that interferes with chewing or swallowing;</p> </li> <li> <p>Kaposi's sarcoma tumour‐associated oedema that affects function;</p> </li> <li> <p>tumour ulceration that is unresponsive to general local care;</p> </li> <li> <p>life‐threatening Kaposi's sarcoma, deemed by the study authors to require immediate anti‐Kaposi's sarcoma therapy such as chemotherapy. </p> </li> </ul> </li> </ul> </li> </ul> <ul id="CD003256-list-0005"> <li> <p>Progressive disease despite prior treatment. Progression is defined according to ACTG response criteria (<a href="./references#CD003256-bbs2-0068" title="KrownSE , MetrokaC , WernzJC . Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. Journal of Clinical Oncology1989;7(9):1201‐7. ">Krown 1989</a>) as: </p> </li> </ul> <ul class="plain" id="CD003256-list-0006"> <li> <ul id="CD003256-list-0007"> <li> <p>an increase of 25% or more in the size of previously existing lesions;</p> </li> <li> <p>the appearance of new lesions or new sites of disease;</p> </li> <li> <p>a change in the character of 25% or more of the skin or oral lesions from macular to plaque‐like or nodular; </p> </li> <li> <p>the development of new or increasing tumor‐associated edema or effusions also considered to represent disease progression. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD003256-sec-0025"> <h4 class="title">Types of interventions</h4> <p>Any chemotherapeutic regimen in combination with HAART compared to HAART alone, chemotherapy versus HAART, and comparisons between chemotherapy regimens both the pre‐HAART era and while on HAART. For this review, HAART is defined as a combination of three or more antiretroviral agents, either taken individually or in fixed‐dose combinations, as opposed to single or dual‐drug therapy. </p> </section> <section id="CD003256-sec-0026"> <h4 class="title">Types of outcome measures</h4> <section id="CD003256-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003256-list-0008"> <li> <p>Mortality</p> </li> <li> <p>Progression of Kaposi's sarcoma</p> </li> <li> <p>Clinical response (complete, partial and no response), which includes assessment of the number of lesions, size and oedema (<a href="./references#CD003256-bbs2-0068" title="KrownSE , MetrokaC , WernzJC . Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. Journal of Clinical Oncology1989;7(9):1201‐7. ">Krown 1989</a>)  </p> </li> </ul> </p> </section> <section id="CD003256-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003256-list-0009"> <li> <p>Time to response</p> </li> <li> <p>Adverse events (including toxicity, worsening of co‐existent disease or both)</p> </li> <li> <p>Kaposi's sarcoma immune reconstitution inflammatory syndrome (IRIS)</p> </li> <li> <p>Adherence</p> </li> <li> <p>Quality of life</p> </li> </ul> </p> </section> </section> </section> <section id="CD003256-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003256-sec-0030"> <h4 class="title">Electronic searches</h4> <p>We formulated a comprehensive and exhaustive search strategy in order to identify all relevant studies regardless of language or publication status (published, unpublished, in press and in progress) (<a href="#CD003256-tbl-0010">Table 1</a>; <a href="#CD003256-tbl-0011">Table 2</a>; <a href="#CD003256-tbl-0012">Table 3</a>). Full details of the Cochrane HIV/AIDS Review Group methods and the journals handsearched are published in the section on Collaborative Review Groups in <i>The Cochrane Library</i> (<a href="./references#CD003256-bbs2-0057" title="Cochrane HIV/AIDS Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2011, Issue 1. Art. No.: HIV. ">Cochrane HIV/AIDS Group 2011</a>). </p> <div class="table" id="CD003256-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table 1. Cochrane CENTRAL search strategy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Search</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [Sarcoma, Kaposi] explode all trees</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>kaposi or karposi or KS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [Herpesvirus 8, Human] explode all trees</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hhv‐8 or hhv8 or KSHV or " human herpes virus 8" or "human herpesvirus 8"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#1 or #2 or #3 or #4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [HIV Infections] explode all trees</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [HIV] explode all trees</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hiv or hiv‐1* or hiv‐2* or hiv1 or hiv2 or HIV INFECT* or HUMAN IMMUNODEFICIENCY VIRUS or HUMAN IMMUNEDEFICIENCY VIRUS or HUMAN IMMUNE‐DEFICIENCY VIRUS or HUMAN IMMUNO‐DEFICIENCY VIRUS or HUMAN IMMUN* DEFICIENCY VIRUS or ACQUIRED IMMUNODEFICIENCY SYNDROME or ACQUIRED IMMUNEDEFICIENCY SYNDROME or ACQUIRED IMMUNO‐DEFICIENCY SYNDROME or ACQUIRED IMMUNE‐DEFICIENCY SYNDROME or ACQUIRED IMMUN* DEFICIENCY SYNDROME </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [Lymphoma, AIDS‐Related] this term only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [Sexually Transmitted Diseases, Viral] this term only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#6 or #7 or #8 or #9 or #10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#5 and #11 from 1980 to 2012, in Trials (Word variations have been searched)</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003256-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Table 2. PubMed search strategy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Search</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Query</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search ((#1 AND #2 AND #10)) AND ("1980/01/01"[Date ‐ Publication] : "2012/11/0"[Date ‐ Publication]) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (#1 AND #2 AND #10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search ((observational[tiab] AND (study[tiab] OR studies[tiab]))</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (evaluation studies as topic[mh:noexp] OR (evaluation[tiab] AND (study[tiab] OR studies[tiab])) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (cross‐sectional studies[mh] OR cross section*[tiab])</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (case control studies[mh] OR case control[tiab])</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search ((follow up[tiab] OR prospective[tiab] OR longitudinal[tiab] OR retrospective[tiab]) AND (study[tiab] OR studies[tiab])) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (cohort studies[mh] OR cohort[tiab] OR cohorts[tiab])</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (randomised controlled trial [pt] OR controlled clinical trial [pt] OR randomised [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh]) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search sarcoma, kaposi[mh] OR kaposi*[tiab] OR karposi*[tiab] OR KS[tiab] OR herpesvirus 8, human[mh] OR human herpes virus 8[tiab] OR human herpesvirus 8[tiab] OR hhv‐8[tiab] OR hhv8[tiab] OR KSHV[tiab] </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv‐1*[tiab] OR hiv‐2*[tiab] OR hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR human immuno‐deficiency virus[tiab] OR human immune‐deficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR acquired immuno‐deficiency syndrome[tiab] OR acquired immune‐deficiency syndrome[tiab] OR ((acquired immun*[tiab]) AND (deficiency syndrome[tiab])) OR "sexually transmitted diseases, Viral"[MeSH:NoExp]) </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD003256-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Table 3. EMBASE search strategy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Query</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#1 AND #13 AND #14 AND [embase]/lim AND [1‐1‐1980]/sd NOT [26‐11‐2012]/sd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#1 AND #13 AND #14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#14</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'kaposi sarcoma'/exp OR 'kaposi sarcoma' OR 'human herpesvirus 8'/exp OR 'human herpesvirus 8' OR kaposi*:ab,ti OR karposi*:ab,ti OR ks:ab,ti OR 'human herpes virus 8':ab,ti OR 'hhv‐8':ab,ti OR hhv8:ab,ti OR kshv:ab,ti </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#13</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#7 OR #8 OR #9 OR #10 OR #11 OR #12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'observational study'/exp OR (observational NEXT/1 (study OR studies)):ab,ti</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'evaluation'/exp OR (evaluation NEXT/1 (study OR studies)):ab,ti</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'cross‐sectional study'/exp OR (cross NEXT/1 section*):ab,ti</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'case control study'/exp OR 'case control':ab,ti</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'cohort analysis'/exp OR 'cohort analysis' OR 'longitudinal study'/exp OR 'longitudinal study' OR 'prospective study'/exp OR 'prospective study' OR 'follow up'/exp OR 'follow up' OR cohort*:ab,ti OR 'longitudinal studies':ab,ti OR 'prospective studies':ab,ti </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#2 NOT #6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#3 NOT #5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#3 AND #4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'human'/de</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'animal'/de OR 'nonhuman'/de OR 'animal experiment'/de</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'randomised controlled trial'/de OR 'randomised controlled trial (topic)'/exp OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR placebo*:ab,ti OR 'crossover procedure'/de OR 'double‐blind procedure'/de OR 'single‐blind procedure'/de OR (doubl* NEAR/3 blind*):ab,ti OR (singl* NEAR/3 blind*):ab,ti OR crossover*:ab,ti OR cross+over*:ab,ti OR (cross NEXT/1 over*):ab,ti </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'human immunodeficiency virus infection'/exp OR 'human immunodeficiency virus'/exp OR 'human immunodeficiency virus':ab,ti OR 'human immuno+deficiency virus':ab,ti OR 'human immunedeficiency virus':ab,ti OR 'human immune+deficiency virus':ab,ti OR hiv:ab,ti OR 'hiv‐1':ab,ti OR 'hiv‐2':ab,ti OR 'acquired immunodeficiency syndrome':ab,ti OR 'acquired immuno+deficiency syndrome':ab,ti OR 'acquired immunedeficiency syndrome':ab,ti OR 'acquired immune+deficiency syndrome':ab,ti </p> </td> </tr> </tbody> </table> </div> <p>We searched the Cochrane CENTRAL and MEDLINE databases on November 9, 2012 (1980 to 2012); EMBASE and GATEWAY on November 26, 2012 (1980 to 2014). An updated search of the databases was done on July 4, 2014. </p> <p> <ul id="CD003256-list-0010"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) 2012 (Issue 10);</p> </li> <li> <p>MEDLINE;</p> </li> <li> <p>EMBASE;</p> </li> <li> <p>GATEWAY.</p> </li> </ul> </p> <p>Along with MeSH terms and relevant keywords, we used the Cochrane highly sensitive search strategy for identifying reports of randomised controlled trials in MEDLINE and the Cochrane HIV/AIDS Group's existing validated strategies for identifying references relevant to HIV infection and AIDS. The search strategy was iterative, in that we searched the references of included studies for additional relevant references. There was no language restriction. </p> <p>We also searched for unpublished and ongoing trials using relevant search terms in:</p> <p> <ul id="CD003256-list-0011"> <li> <p>the US National Institutes of Health's Clinical Trials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); and </p> </li> <li> <p>the WHO Clinical Trials Registry Platform (ICTRP).</p> </li> </ul> </p> </section> <section id="CD003256-sec-0031"> <h4 class="title">Searching other resources</h4> <p>We searched the Aegis archive of HIV/AIDS conference abstracts (<a href="http://www.aegis.org/" target="_blank">http://www.aegis.org/</a>) on 24 May 2013. Aegis includes abstracts for the following conferences: </p> <p> <ul id="CD003256-list-0012"> <li> <p>International AIDS Society, International AIDS Conference (IAC), 1985 to 2006;</p> </li> <li> <p>Conference on Retroviruses and Opportunistic Infections (CROI), 1994 to 2008;</p> </li> <li> <p>European AIDS Society Conference, 2001 and 2003;</p> </li> <li> <p>International AIDS Society, Conference on HIV Pathogenesis, Treatment and Prevention (IAS), 2001 to 2005; </p> </li> <li> <p>British HIV/AIDS Association, 2001 to 2010;</p> </li> <li> <p>US National HIV Prevention Conference, 1999, 2001, 2003, 2005 2007, 2009 and 2011.</p> </li> </ul> </p> <p>We also searched the CROI and International AIDS Society websites for abstracts presented at conferences subsequent to those listed above (CROI, 2009 to 2012; IAC, 2008 to 2010; IAS, 2007 to 2011). In addition, we contacted experts in the field to identify further potentially eligible studies. </p> </section> </section> <section id="CD003256-sec-0032"> <h3 class="title" id="CD003256-sec-0032">Data collection and analysis</h3> <section id="CD003256-sec-0033"> <h4 class="title">Selection of studies</h4> <p>Two authors (GO and CO) independently read the titles and abstracts from the search output to identify potentially eligible studies. We obtained full‐text articles for all citations identified as potentially eligible and two authors independently inspected these to establish the relevance of the article using the prespecified criteria. We resolved all disagreements by discussion and by contacting the third author (EF). </p> </section> <section id="CD003256-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>We designed a standardised data extraction form and two authors independently extracted data onto this. We extracted the following characteristics from each included study: </p> <p> <ul id="CD003256-list-0013"> <li> <p>Administrative details: author(s); published or unpublished; year of publication; year(s) in which study was conducted. </p> </li> <li> <p>Details of the study: study design; type, duration and completeness of follow‐up; study location. </p> </li> <li> <p>Details of participants: age; gender; clinical characteristics (e.g. baseline CD4 cell count, viral load, opportunistic infections). </p> </li> <li> <p>Details of treatment.</p> </li> <li> <p>Details of outcomes.</p> </li> <li> <p>Details necessary for 'Risk of bias' assessment.</p> </li> </ul> </p> </section> <section id="CD003256-sec-0035"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias of each study using the 'Risk of bias' assessment tool described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003256-bbs2-0065" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreement by discussion. The Cochrane approach assesses risk of bias in individual studies across six domains: sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting and other potential biases. </p> <section id="CD003256-sec-0036"> <h5 class="title">Sequence generation (checking for selection bias)</h5> <p> <ul id="CD003256-list-0014"> <li> <p>Adequate: investigators described a random component in the sequence generation process, such as the use of random number table, coin tossing, card or envelope shuffling. </p> </li> <li> <p>Inadequate: investigators described a non‐random component in the sequence generation process, such as the use of odd or even date of birth, algorithm based on the day or date of birth, hospital or clinic record number. </p> </li> <li> <p>Unclear: insufficient information to permit judgement of the sequence generation process.</p> </li> </ul> </p> </section> <section id="CD003256-sec-0037"> <h5 class="title">Allocation concealment (checking for selection bias)</h5> <p> <ul id="CD003256-list-0015"> <li> <p>Adequate: participants and the investigators enrolling participants cannot foresee assignment (e.g. central allocation or sequentially numbered, opaque, sealed envelopes). </p> </li> <li> <p>Inadequate: participants and investigators enrolling participants can foresee upcoming assignment (e.g. an open random allocation schedule, a list of random numbers), or envelopes were unsealed, non‐opaque or not sequentially numbered. </p> </li> <li> <p>Unclear: insufficient information to permit judgement of the allocation concealment or the method is not described. </p> </li> </ul> </p> </section> <section id="CD003256-sec-0038"> <h5 class="title">Blinding (checking for performance bias and detection bias)</h5> <p> <ul id="CD003256-list-0016"> <li> <p>Adequate: blinding of the participants, key study personnel and outcome assessor and it is unlikely that the blinding could have been broken. Not blinded but a situation where non‐blinding is unlikely to introduce bias. </p> </li> <li> <p>Inadequate: no blinding or incomplete blinding when the outcome is likely to be influenced by lack of blinding. </p> </li> <li> <p>Unclear: insufficient information to permit judgement of the adequacy or otherwise of the blinding. </p> </li> </ul> </p> </section> <section id="CD003256-sec-0039"> <h5 class="title">Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations) </h5> <p> <ul id="CD003256-list-0017"> <li> <p>Adequate: no missing outcome data, reasons for missing outcome data are unlikely to be related to true outcome or missing outcome data are balanced in numbers across groups. </p> </li> <li> <p>Inadequate: reasons for missing outcome data are likely to be related to true outcome, with either imbalance in numbers across groups or reasons for missing data. </p> </li> <li> <p>Unclear: insufficient reporting of attrition or exclusions.</p> </li> </ul> </p> </section> <section id="CD003256-sec-0040"> <h5 class="title">Selective reporting</h5> <p> <ul id="CD003256-list-0018"> <li> <p>Adequate: a protocol is available and clearly states that the primary outcome is the same as in the final trial report. </p> </li> <li> <p>Inadequate: the primary outcome differs between the protocol and final trial report.</p> </li> <li> <p>Unclear: no trial protocol is available or there is insufficient reporting to determine whether selective reporting is present. </p> </li> </ul> </p> </section> <section id="CD003256-sec-0041"> <h5 class="title">Other sources of bias</h5> <p> <ul id="CD003256-list-0019"> <li> <p>Adequate: there is no evidence of bias from other sources.</p> </li> <li> <p>Inadequate: there is potential bias present from other sources (e.g. early stopping of trial, fraudulent activity, extreme baseline imbalance or bias related to specific study design). </p> </li> <li> <p>Unclear: insufficient information to permit judgement of other forms of bias.</p> </li> </ul> </p> <p>For non‐randomised studies, we used the Newcastle‐Ottawa Scale to assess the risk of bias in three major areas: selection of study groups, comparability of groups and ascertainment of outcomes (<a href="./appendices#CD003256-sec-0117">Appendix 1</a>). </p> </section> </section> <section id="CD003256-sec-0042"> <h4 class="title">Measures of treatment effect</h4> <p>For randomised controlled trials and observational studies, we calculated the risk ratio (RR) for dichotomous outcomes with a 95% confidence interval (CI). For continuous data we calculated the mean difference with a 95% CI. </p> </section> <section id="CD003256-sec-0043"> <h4 class="title">Dealing with missing data</h4> <p>We did not impute missing data. We contacted the authors of the included studies if there were any missing or unclear data. </p> </section> <section id="CD003256-sec-0044"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess statistical heterogeneity by visually inspecting the forest plots to detect overlapping CIs, applying the Chi<sup>2</sup> test (P value &lt; 0.10 considered statistically significant) and by using the I<sup>2</sup> statistic, where an I<sup>2</sup> value of greater than 75% represents substantial heterogeneity. The studies differed significantly in terms of participants and interventions, precluding any meta‐analysis. </p> </section> <section id="CD003256-sec-0045"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not explore the likelihood of reporting bias using funnel plots, since we did not combine any of the studies in a meta‐analysis. However, we conducted a comprehensive search to identify all relevant studies. </p> </section> <section id="CD003256-sec-0046"> <h4 class="title">Data synthesis</h4> <p>We have presented the results of individual studies narratively since meta‐analysis was not possible. </p> <section id="CD003256-sec-0047"> <h5 class="title">Quality of evidence</h5> <p>We assessed the quality of evidence across each outcome measure using the GRADE approach. The quality rating across studies has four levels: high, moderate, low or very low. Randomised trials are categorised as high quality but can be downgraded; similarly, observational studies are categorised as low quality and can be downgraded or upgraded. We used the GRADEpro software to generate GRADE evidence profiles and 'Summary of findings' tables. </p> </section> </section> <section id="CD003256-sec-0048"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to explore heterogeneity by subgroup analyses. However, we did not combine any of the studies in a meta‐analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003256-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003256-sec-0049"></div> <section id="CD003256-sec-0050"> <h3 class="title">Description of studies</h3> <section id="CD003256-sec-0051"> <h4 class="title">Results of the search</h4> <p>See the PRISMA flow diagram (<a href="#CD003256-fig-0001">Figure 1</a>) and the <a href="./references#CD003256-sec-0128" title="">Characteristics of included studies</a> table for details. </p> <div class="figure" id="CD003256-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD003256-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>We conducted a search for studies in the various databases listed in <a href="#CD003256-sec-0029">Search methods for identification of studies</a> in May 2013 and an updated search in July 2014. We obtained a total of 3615 titles and abstracts after de‐duplication of references. Two authors independently scanned through the titles and abstracts using our prespecified inclusion criteria. We identified 65 potentially eligible studies and obtained the full‐text articles. Nine studies that met our inclusion criteria were included. We gave reasons for excluding any potentially eligible study. See <a href="./references#CD003256-sec-0129" title="">Characteristics of excluded studies</a>. </p> </section> <section id="CD003256-sec-0052"> <h4 class="title">Included studies</h4> <section id="CD003256-sec-0053"> <h5 class="title">Types of studies</h5> <p>We included six randomised controlled trials (<a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a>; <a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a>; <a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a>; <a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a>; <a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a>; <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>) and three observational studies (<a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a>; <a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a>; <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a>). Where multiple papers were published on the same cohort of patients, we refer to the primary study only, but refer to additional publications in the <a href="./references#CD003256-sec-0128" title="">Characteristics of included studies</a>. </p> </section> <section id="CD003256-sec-0054"> <h5 class="title">Types of participants</h5> <p>Of the nine included studies, seven had participants with a mix of T0 and T1 Kaposi's sarcoma (<a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a>; <a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a>; <a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a>; <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a>; <a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a>; <a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a>; <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>). Two studies had only T1 disease patients (<a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a>; <a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a>). For all studies, we extracted data only for participants meeting criteria of severe disease, as defined above. All included studies did measure ACTG stage, and ultimately were able to provide results according to stage after communication with study authors. Therefore, for all included papers, only patients with T1 disease were included. Of note, the two studies included in the prior Cochrane review on Kaposi's sarcoma were not included in the current review due to a mix of Kaposi's sarcoma stages; T1 disease patients could not be separated from T0 (<a href="./references#CD003256-bbs2-0034" title="NorthfeltDW , DezubeBJ , ThommesJA , MillerBJ , FischlMA , Freidman‐KienA , et al. Pegylated liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS related Kaposi's sarcoma: results of a randomised phase III clinical trial. Journal of Clinical Oncology1998;16(7):2445‐51. ">Northfelt 1998</a>; <a href="./references#CD003256-bbs2-0045" title="StewartS , JablonowskiH , GoebelFD , ArastehK , SpittleM , RiosA , et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1998;16(2):683‐91. ">Stewart 1998</a>). </p> <p>Participants in all the studies were HIV‐infected adults with biopsy‐proven Kaposi's sarcoma. <a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a> included 100 patients with T1 Kaposi's sarcoma (out of a total of 112 treatment‐naive HIV‐infected patients). It should be noted that T1 patients in this study were deemed by the author not to require "urgent" chemotherapy. <a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a> included 49 patients with T1 Kaposi's sarcoma out of a total of 73 patients aged 18 years and above. <a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a> included 254 patients of which 79 were T1 Kaposi's sarcoma patients (<a href="./references#CD003256-bbs2-0028" title="LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Letang 2013</a> included a later version of Bower's UK cohort of 129 T1 Kaposi's sarcoma patients). <a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a> included 46 patients with T1 disease out of a total of 79 patients. <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a> included a total of 470 antiretroviral therapy (ART)‐naive patients, of which 376 had T1 Kaposi's sarcoma. <a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a> included 10 patients with T1 disease out of a total of 28 HIV‐infected patients with moderate to advanced Kaposi's sarcoma. <a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a> included 29 HIV‐infected males with pulmonary (T1) Kaposi's sarcoma. <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a> included 34 T1 Kaposi's sarcoma patients out of a total of 44 homosexual or bisexual men. <a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a> included 227 HIV‐infected adults with T1 disease. All participants met this review’s criteria of having severe KS. </p> </section> <section id="CD003256-sec-0055"> <h5 class="title">Types of interventions</h5> <p>None of the included studies with the same study design compared similar interventions.</p> <p><a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a> compared HAART plus doxorubicin, bleomycin and vincristine (ABV) versus HAART alone. There were a total of 100 T1 Kaposi's sarcoma patients, with 50 in the HAART plus ABV group and 50 in the HAART alone group. Chemotherapy was started within one month of initiation of HAART. Of note, when ABV was not available, oral etoposide was substituted. </p> <p><a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a> compared HAART plus pegylated liposomal doxorubicin (PLD) versus HAART alone. There were a total of 10 T1 Kaposi's sarcoma patients, with five in the HAART plus PLD group and five in the HAART alone group. HAART and chemotherapy were started simultaneously at the beginning of the study. </p> <p>The <a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a> (<a href="./references#CD003256-bbs2-0028" title="LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Letang 2013</a>, Bower 2014) UK cohort included patients on HAART alone as well as patients on HAART plus liposomal anthracycline. Of the 79 T1 patients in the study, there were a total of 73 patients with severe Kaposi's sarcoma in the HAART alone and HAART plus chemotherapy groups. <a href="./references#CD003256-bbs2-0028" title="LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Letang 2013</a>, a pooled analysis of four cohort studies, included patients from the <a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a> UK cohort. There were 129 T1 disease patients out of a total of 213 patients, with 65 T1 patients in the HAART plus liposomal anthracycline group and 64 T1 patients in the HAART alone group. All T1 Kaposi's sarcoma patients in this study were meant to receive chemotherapy as per protocol; patients who received HAART alone were therefore exceptions. The original <a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a> cohort was not designed with the intent to compare these two groups. </p> <p><a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a> compared HAART plus paclitaxel versus HAART plus PLD. There were a total of 24 participants in the paclitaxel group and 25 in the PLD group. Participants were required to receive HAART for at least 14 days before study enrolment. </p> <p><a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a> compared HAART plus pegylated liposomal doxorubicin versus HAART plus liposomal daunorubicin. Only 76 out of 80 patients in the overall study were on ART. There were a total of 46 T1 Kaposi's sarcoma patients with 34 in the PLD group and 12 in the liposomal daunorubicin group. The time interval between commencement of HAART and chemotherapy, and the type of HAART regimen received were not described. </p> <p><a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a> compared liposomal daunorubicin versus ABV in the pre‐HAART era. There were a total of 227 participants, with 116 in the liposomal daunorubicin group and 111 in the ABV group. </p> <p><a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>was a four‐arm trial that compared supportive care versus supportive care plus oral etoposide, ABV and radiotherapy. There were a total of 378 ART‐naive T1 Kaposi's sarcoma patients, of which 178 were in the oral etoposide (90 patients) and ABV (88 patients) groups. </p> <p>There were four intervention groups in <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a>: alpha‐2 interferon, ABV, bleomycin and a no treatment group. Ten patients with limited Kaposi's sarcoma received alpha‐2 interferon plus zidovudine, 24 patients with advanced Kaposi's sarcoma (12 in each group) received either intramuscular bleomycin or low‐dose ABV, and 10 "poor risk" patients received no treatment due to financial constraint. </p> <p>In <a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a>, also performed in the pre‐HAART era, 17 out of the 20 participants in the liposomal doxorubicin group received antiretroviral therapy. In the group that received conservative management, 4 out of the 9 participants had bleomycin and vinblastine or vincristine; five had no chemotherapy, and 2 of the 5 participants that did not receive chemotherapy had interferon alpha. </p> </section> <section id="CD003256-sec-0056"> <h5 class="title">Types of outcome measures</h5> <p>The outcomes reported were mortality (<a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a>; <a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a>; <a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a>; <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a>; <a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a>; <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>), Kaposi's sarcoma immune reconstitution inflammatory syndrome (IRIS) (<a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a>), tumour response (<a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a>; <a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a>; <a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a>; <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a>; <a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a>; <a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a>; <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>), adverse events (<a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a>; <a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a>; <a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a>; <a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a>; <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a>; <a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a>; <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>), time to response (<a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a>; <a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a>; <a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a>; <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a>; <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>) and quality of life (<a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a>; <a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a>; <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>). However, Cianfrocca and Olweny did not report quality of life according to disease stage. None of the included studies reported outcome data on adherence. </p> </section> <section id="CD003256-sec-0057"> <h5 class="title">Settings</h5> <p>The studies were conducted in various settings including: Germany (<a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a>), South Africa (<a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a>), Spain (<a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a>), the UK (<a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a>), the USA (<a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a>; <a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a>; <a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a>), Venezuela (<a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a>) and Zimbabwe (<a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>). </p> </section> </section> </section> <section id="CD003256-sec-0058"> <h3 class="title">Risk of bias in included studies</h3> <p>For assessment results, please see the 'Risk of bias' graph and summary (<a href="#CD003256-fig-0002">Figure 2</a>; <a href="#CD003256-fig-0003">Figure 3</a>), and the Newcastle‐Ottawa quality assessment scale for included cohort studies (<a href="./appendices#CD003256-sec-0118">Appendix 2</a>). The overall methodological quality of the studies was acceptable. We obtained additional information by contacting the study authors to be able to make informed assessments where necessary. </p> <div class="figure" id="CD003256-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003256-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003256-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003256-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD003256-sec-0059"> <h4 class="title">Allocation</h4> <p>We did not find information on the method of sequence generation and allocation concealment in any of the studies except <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>. </p> </section> <section id="CD003256-sec-0060"> <h4 class="title">Blinding</h4> <p>There was no blinding to intervention in any of the studies. However, the reported outcomes were objective and not likely to be affected by lack of blinding. In the <a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a> trial, an independent AIDS expert without knowledge of the patient evaluated the outcome. </p> </section> <section id="CD003256-sec-0061"> <h4 class="title">Incomplete outcome data</h4> <p>There was no differential loss to follow‐up in any of the studies.</p> </section> <section id="CD003256-sec-0062"> <h4 class="title">Selective reporting</h4> <p>We did not find any evidence of selective outcome reporting in any of the studies.</p> </section> <section id="CD003256-sec-0063"> <h4 class="title">Other potential sources of bias</h4> <p>The <a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a> trial was terminated prematurely due to slow accrual. There were some reported baseline imbalances in the <a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a> and <a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a> studies. The <a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a> study patients with T1 disease were deemed not to "urgently" require chemotherapy, and therefore may have been less sick than the T1 patients in other studies included in this review. All T1 KS patients in <a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a> were meant to receive chemotherapy as per protocol, patients who received HAART alone were therefore exceptions. We did not explore the potential for publication bias since we did not combine any of the studies in a meta‐analysis. However, we conducted a comprehensive search to identify all relevant studies. </p> <p><b>For non‐randomised studies</b>: (<a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a>) had a cohort that was representative of HIV‐infected adults with Kaposi’s sarcoma and adjusted for potential confounders. <a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a> and <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a> did not report adjusting for any other potential confounders for all outcomes of interest. All included observational studies described complete follow up of the study participants or characteristics of the participants lost to follow up (<a href="./appendices#CD003256-sec-0118">Appendix 2</a>). </p> </section> </section> <section id="CD003256-sec-0064"> <h3 class="title" id="CD003256-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD003256-tbl-0001"><b>Summary of findings for the main comparison</b> HAART + ABV compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</a>; <a href="./full#CD003256-tbl-0002"><b>Summary of findings 2</b> HAART + pegylated liposomal doxorubicin compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</a>; <a href="./full#CD003256-tbl-0003"><b>Summary of findings 3</b> HAART + liposomal anthracycline compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</a>; <a href="./full#CD003256-tbl-0004"><b>Summary of findings 4</b> HAART + paclitaxel compared to HAART + pegylated liposomal doxorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</a>; <a href="./full#CD003256-tbl-0005"><b>Summary of findings 5</b> HAART + pegylated liposomal doxorubicin compared to HAART + liposomal daunorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</a>; <a href="./full#CD003256-tbl-0006"><b>Summary of findings 6</b> Liposomal daunorubicin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</a>; <a href="./full#CD003256-tbl-0007"><b>Summary of findings 7</b> Oral etoposide compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</a>; <a href="./full#CD003256-tbl-0008"><b>Summary of findings 8</b> Bleomycin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</a>; <a href="./full#CD003256-tbl-0009"><b>Summary of findings 9</b> Liposomal doxorubicin compared to conservative management for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</a> </p> <section id="CD003256-sec-0065"> <h4 class="title">Highly active antiretroviral therapy (HAART) plus chemotherapy versus HAART alone</h4> <section id="CD003256-sec-0066"> <h5 class="title">Randomised controlled trials</h5> <section id="CD003256-sec-0067"> <h6 class="title">HAART plus doxorubicin, bleomycin and vincristine (ABV) versus HAART alone</h6> <p>In <a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a>, in the HAART plus ABV group, ABV was started within one month of initiation of HAART. Of note, when ABV was not available, oral Etoposide was given. This alternative chemotherapy regimen was used in 31% of patients that received chemotherapy overall. </p> <p>The HAART regimen consisted of a fixed‐dose combination of stavudine (40 mg), lamivudine (150 mg) and nevirapine 200 mg. </p> <p>The outcomes reported were:</p> <section id="CD003256-sec-0068"> <p><b>Mortality</b></p> <p>In the T1 Kaposi's sarcoma group, there were a total of 11 deaths out of 50 participants in the HAART plus ABV group compared to 12 deaths out of 50 in the HAART alone group (RR 0.92; 95% CI 0.45 to 1.88) (<a href="./references#CD003256-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD003256-sec-0069"> <p><b>Progression of Kaposi's sarcoma</b></p> <p>One out of 50 participants had progressive disease in the HAART plus ABV group, compared to 10 participants out of 50 with progressive disease in the HAART alone group(RR 0.10; 95% CI 0.01 to 0.75) (<a href="./references#CD003256-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD003256-sec-0070"> <p><b>Clinical response (includes complete, partial and no response)</b></p> <p> <ul id="CD003256-list-0020"> <li> <p>Complete response</p> </li> </ul> </p> <p>Eight out of 50 participants had a complete response in the HAART plus ABV group, compared to four participants out of 50 with complete response in the HAART alone group(RR 2.0; 95% CI 0.64 to 6.22) (<a href="./references#CD003256-fig-0006" title="">Analysis 1.3</a>). </p> <p> <ul id="CD003256-list-0021"> <li> <p>Partial response</p> </li> </ul> </p> <p>Twenty‐four participants in the HAART plus ABV group had a partial response compared to 14 participants in the HAART alone group(RR 1.71; 95% CI 1.01 to 2.91). </p> <p> <ul id="CD003256-list-0022"> <li> <p>The overall response rate (complete and partial) in the HAART plus ABV group was 32 out of 50 participants compared to 18 in the HAART alone group(RR 1.78; 95% CI 1.16 to 2.72). </p> </li> </ul> <ul id="CD003256-list-0023"> <li> <p>Stable disease (no response)</p> </li> </ul> </p> <p>There were no participants with stable disease in the HAART plus ABV group and eight participants in the HAART alone group had stable disease. </p> </section> <section id="CD003256-sec-0071"> <p><b>Adverse events</b></p> <p>Twenty‐three participants in the HAART plus ABV group and 26 in the HAART alone group had grade 3 to 5 adverse events (including Kaposi's sarcoma immune reconstitution inflammatory syndrome (IRIS): four in the HAART plus ABV group and one patient in the HAART alone group (RR 0.88; 95% CI 0.59 to 1.32) (<a href="./references#CD003256-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD003256-sec-0072"> <h6 class="title">HAART plus pegylated liposomal doxorubicin (PLD) versus HAART alone</h6> <p><a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a> included both T1 and T0 Kaposi's sarcoma patients. We present results only for participants with T1 Kaposi's sarcoma. HAART and chemotherapy were started simultaneously at the beginning of the study (there were two antiretroviral therapy (HAART) treatment‐naive patients). The HAART regimen was protease inhibitor (PI) based, non‐nucleoside reverse transcriptase (NNRTI) based or PI plus NNRTI. </p> <p>The outcomes reported were:</p> <section id="CD003256-sec-0073"> <p><b>Clinical response (includes complete, partial and no response)</b></p> <p>There were a total of 10 T1 Kaposi's sarcoma patients, with five in the HAART plus PLD group and five in the HAART alone group. The authors combined the results for both partial and complete response. In the HAART plus PLD group, four participants had a complete/partial response, while none responded in the HAART alone group. PLD plus HAART appeared to increase the rate of both partial and complete response compared to HAART alone. However, this difference was not statistically significant (risk ratio (RR) 9; 95% confidence interval (CI) 0.61 to 133.08) (<a href="./references#CD003256-fig-0008" title="">Analysis 2.1</a>). </p> </section> </section> </section> <section id="CD003256-sec-0074"> <h5 class="title">Prospective cohort study</h5> <section id="CD003256-sec-0075"> <h6 class="title">HAART plus liposomal anthracycline versus HAART alone</h6> <p>In <a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a> (including Bower 2014 and <a href="./references#CD003256-bbs2-0028" title="LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Letang 2013</a>), there were 163 participants in the HAART alone group (131 were antiretroviral‐naive and 32 were on HAART at the time of diagnosis), of which five participants had T1 disease. There were 73 patients in the HAART plus liposomal anthracycline group, of which 68 had T1 Kaposi's sarcoma. This study was not designed to compare different treatment regimens for patients with T1 disease. Specifically, the clinic followed guidelines that all T1 patients should be treated with HAART plus liposomal anthracyclines, therefore T1 patients who were treated with HAART alone were particular exceptions. Outcome data were not presented according to Kaposi's sarcoma staging. Updated data from the same cohort were similarly presented in Bower 2014. <a href="./references#CD003256-bbs2-0028" title="LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Letang 2013</a> included Bower's UK cohort of 213 patients, of which 129 had T1 Kaposi's sarcoma, with 65 patients in the HAART plus chemotherapy group and 64 in the HAART alone group. In order to ascertain outcome specific to stage, the data reported below were provided after communication with the author of <a href="./references#CD003256-bbs2-0028" title="LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Letang 2013</a>, and represent unpublished <a href="./references#CD003256-bbs2-0028" title="LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Letang 2013</a> data. </p> <p>The outcomes reported were:</p> <section id="CD003256-sec-0076"> <p><b>Mortality/overall 12‐month survival</b></p> <p>A total of five out of 65 T1 participants in the HAART plus liposomal anthracycline group died at the end of 12 months compared to four out of 64 participants in the HAART alone group (RR 1.23; 95% CI 0.35 to 4.38) (<a href="./references#CD003256-fig-0009" title="">Analysis 3.1</a>). </p> </section> <section id="CD003256-sec-0077"> <p><b>Kaposi's sarcoma IRIS</b></p> <p>Four out of 65 T1 participants in the HAART plus liposomal anthracycline group developed Kaposi's sarcoma IRIS compared to eight out of 64 participants in the HAART alone group(RR 0.49; 95% CI 0.16 to 1.55) (<a href="./references#CD003256-fig-0010" title="">Analysis 3.2</a>). </p> </section> </section> </section> </section> <section id="CD003256-sec-0078"> <h4 class="title">HAART plus chemotherapy versus HAART plus another chemotherapy regimen</h4> <section id="CD003256-sec-0079"> <h5 class="title">Randomised controlled trials</h5> <section id="CD003256-sec-0080"> <h6 class="title">HAART plus paclitaxel versus HAART plus PLD</h6> <p>In <a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a>, there were a total of 49 T1 Kaposi's sarcoma patients, with 24 in the paclitaxel group and 25 in the PLD group. Participants were required to receive HAART (PI, a non‐nucleoside reverse transcriptase inhibitor without a PI or both) for at least 14 days before study enrolment. Mortality and adverse events results were not available according to Kaposi's sarcoma staging. </p> <p>The outcomes reported were:</p> <section id="CD003256-sec-0081"> <p><b>Progression of Kaposi's sarcoma</b></p> <p>One out of 24 participants had progressive disease in the paclitaxel group, compared to one participant out of 25 in the PLD group(RR 1.04; 95% CI 0.07 to 15.73) (<a href="./references#CD003256-fig-0011" title="">Analysis 4.1</a>). </p> </section> <section id="CD003256-sec-0082"> <p><b>Clinical response (includes complete, partial and no response)</b></p> <p> <ul id="CD003256-list-0024"> <li> <p>Complete response</p> </li> </ul> </p> <p>Two out of 24 participants had a complete response in the paclitaxel group, compared to one participant out of 25 in the PLD group(RR 2.08; 95% CI 0.20 to 21.50) (<a href="./references#CD003256-fig-0012" title="">Analysis 4.2</a>). </p> <p> <ul id="CD003256-list-0025"> <li> <p>Partial response</p> </li> </ul> </p> <p>Nine participants had a partial response in both the paclitaxel and PLD groups(RR 1.04; 95% CI 0.50 to 2.17) (<a href="./references#CD003256-fig-0012" title="">Analysis 4.2</a>). </p> <p> <ul id="CD003256-list-0026"> <li> <p>Stable disease (no response)</p> </li> </ul> </p> <p>There were six participants out of 24 with stable disease in the paclitaxel group and 10 participants out of 25 in the PLD group(RR 0.63; 95% CI 0.27 to 1.45) (<a href="./references#CD003256-fig-0012" title="">Analysis 4.2</a>). </p> </section> </section> <section id="CD003256-sec-0083"> <h6 class="title">HAART plus pegylated liposomal doxorubicin (PLD) versus HAART plus liposomal daunorubicin</h6> <p>In <a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a>, there were a total of 46 T1 Kaposi's sarcoma patients, with 34 in the PLD group and 12 in the liposomal daunorubicin group. The time interval between HAART and chemotherapy and the HAART regimen was not described. 95% of patients in the overall trial received HAART. </p> <p>The outcomes reported were:</p> <section id="CD003256-sec-0084"> <p><b>Progression of Kaposi's sarcoma</b></p> <p>There were no participants with progressive disease in either the PLD or liposomal daunorubicin groups. </p> </section> </section> </section> </section> <section id="CD003256-sec-0085"> <h4 class="title">Chemotherapy versus chemotherapy in the pre‐HAART era</h4> <section id="CD003256-sec-0086"> <h5 class="title">Randomised controlled trials</h5> <section id="CD003256-sec-0087"> <h6 class="title">Liposomal daunorubicin versus doxorubicin, bleomycin and vincristine (ABV)</h6> <p>In <a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a>, there were a total of 227 participants, with 116 in the liposomal daunorubicin group and 111 in the ABV group. During the course of the trial, 48 participants (41%) in the liposomal daunorubicin group received concomitant zidovudine therapy, 38 (33%) were treated with didanosine and 24 (21%) received zalcitabine. Among the participants in the ABV group, 47 (42%) received zidovudine, 29 (26%) received didanosine and 22 (20%) were treated with zalcitabine. </p> <p>The outcomes reported were:</p> <section id="CD003256-sec-0088"> <p><b>Mortality</b></p> <p>Median survival time was 369 days for participants in the liposomal daunorubicin group and 342 days for participants in the ABV group. When the analysis was restricted to patients receiving prior zidovudine, survival was improved in the liposomal daunorubicin group as compared to the ABV group (p=0.26; individual level data not provided). </p> </section> <section id="CD003256-sec-0089"> <p><b>Progression of Kaposi's sarcoma</b></p> <p>Nine out of 116 participants had progressive disease in the liposomal daunorubicin group, compared to 11 participants out of 111 in the ABV group(RR 0.78; 95% CI 0.34 to 1.82) (<a href="./references#CD003256-fig-0014" title="">Analysis 6.1</a>). </p> </section> <section id="CD003256-sec-0090"> <p><b>Clinical response (includes complete, partial and no response)</b></p> <p> <ul id="CD003256-list-0027"> <li> <p>Complete response</p> </li> </ul> </p> <p>Three out of 116 participants had a complete response in the liposomal daunorubicin group, compared to one participant out of 111 in the ABV group (RR 2.87; 95% CI 0.3 to 27.19) (<a href="./references#CD003256-fig-0015" title="">Analysis 6.2</a>). </p> <p> <ul id="CD003256-list-0028"> <li> <p>Partial response</p> </li> </ul> </p> <p>Twenty‐six participants out of 116 in the liposomal daunorubicin group had a partial response compared to 30 participants out of 111 in the ABV group(RR 0.83; 95% CI 0.53 to 1.31) (<a href="./references#CD003256-fig-0015" title="">Analysis 6.2</a>). </p> <p> <ul id="CD003256-list-0029"> <li> <p>Overall response</p> </li> </ul> </p> <p>The overall response rate (complete and partial response) in the liposomal daunorubicin group was 29 out of 116 participants compared to 31 out of 111 in the ABV group (RR 0.90; 95% CI 0.58 to 1.38) (<a href="./references#CD003256-fig-0015" title="">Analysis 6.2</a>). </p> <p> <ul id="CD003256-list-0030"> <li> <p>Stable disease (no response)</p> </li> </ul> </p> <p>There were 72 participants out of 116 with stable disease in the liposomal daunorubicin group and 64 participants out of 111 in the ABV group(RR 1.08; 95% CI 0.87 to 1.33) (<a href="./references#CD003256-fig-0015" title="">Analysis 6.2</a>). </p> </section> <section id="CD003256-sec-0091"> <p><b>Adverse events (including toxicity and/or worsening of co‐existent disease)</b></p> <p>One hundred and thirteen out of 116 participants in the liposomal daunorubicin group and 107 out of 111 in the ABV group had clinical adverse events(RR 1.01; 95% CI 0.96 to 1.06) (<a href="./references#CD003256-fig-0016" title="">Analysis 6.3</a>). </p> <p> <ul id="CD003256-list-0031"> <li> <p>The median time to treatment failure was 115 days in the liposomal daunorubicin group and 99 days in the ABV group. </p> </li> </ul> </p> <p><i>Quality of life</i> </p> <p>This was reported in <a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a>. The authors reported that although patients treated with ABV had a gradual decline in the combined QOL score, the differences between the two treatment arms were not statistically significant. </p> </section> </section> <section id="CD003256-sec-0092"> <h6 class="title">Oral etoposide versus ABV</h6> <p>In <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>, there were a total of 178 T1 Kaposi's sarcoma patients with 90 in the oral etoposide group and 88 in the ABV group. No participant received antiretroviral therapy. </p> <p>The outcomes reported were:</p> <section id="CD003256-sec-0093"> <p><b>Mortality</b></p> <p>There were a total of 84 deaths out of 90 participants in the oral etoposide group compared to 76 deaths out of 88 in the ABV group(RR 1.08; 95% CI 0.98 to 1.19) (<a href="./references#CD003256-fig-0017" title="">Analysis 7.1</a>). </p> </section> <section id="CD003256-sec-0094"> <p><b>Clinical response (includes complete, partial and no response)</b></p> <p> <ul id="CD003256-list-0032"> <li> <p>Complete response</p> </li> </ul> </p> <p>There were no participants with complete response in either the oral etoposide or ABV group. </p> </section> </section> </section> <section id="CD003256-sec-0095"> <h5 class="title">Non‐randomised trials</h5> <section id="CD003256-sec-0096"> <h6 class="title">Bleomycin versus ABV</h6> <p>In <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a>, there were 24 patients with severe Kaposi's sarcoma in the bleomycin and ABV groups(12 in each). </p> <p>The outcomes reported were:</p> <section id="CD003256-sec-0097"> <p><b>Mortality</b></p> <p>All 12 participants in the bleomycin only group died compared to 11 deaths out of 12 in the ABV group(RR 1.09; 95% CI 0.87 to 1.36) (<a href="./references#CD003256-fig-0018" title="">Analysis 8.1</a>). </p> </section> <section id="CD003256-sec-0098"> <p><b>Clinical response (includes complete, partial and no response)</b></p> <p> <ul id="CD003256-list-0033"> <li> <p>Complete response</p> </li> </ul> </p> <p>None of the patients in either the bleomycin or ABV group had a complete response.</p> <p> <ul id="CD003256-list-0034"> <li> <p>Partial response</p> </li> </ul> </p> <p>None of the patients in the bleomycin group had a partial response compared to four patients in the ABV group(RR 0.11; 95% CI 0.01 to 1.86) (<a href="./references#CD003256-fig-0019" title="">Analysis 8.2</a>). </p> <p> <ul id="CD003256-list-0035"> <li> <p>Stable disease</p> </li> </ul> </p> <p>Seven patients in the bleomycin group compared to eight in the ABV group had stable disease(RR 0.88; 95% CI 0.47 to 1.63) (<a href="./references#CD003256-fig-0019" title="">Analysis 8.2</a>). </p> <p> <ul id="CD003256-list-0036"> <li> <p>Progression</p> </li> </ul> </p> <p>Five participants in the bleomycin group had progressive disease compared to none in the ABV group (RR 11; 95% CI 0.67 to 179.29) (<a href="./references#CD003256-fig-0019" title="">Analysis 8.2</a>). </p> </section> <section id="CD003256-sec-0099"> <p><b>Adverse events</b></p> <p>There were five reported adverse events (fever) in the bleomycin only group and none in the ABV group(RR 11; 95% CI 0.67 to 179.29) (<a href="./references#CD003256-fig-0020" title="">Analysis 8.3</a>). </p> </section> <section id="CD003256-sec-0100"> <p><b>Time to mortality</b></p> <p> <ul id="CD003256-list-0037"> <li> <p>The median survival time (in months) was 11 (6 to 20) in the bleomycin only group and 13 (7 to 36) in the ABV group. </p> </li> </ul> </p> </section> </section> <section id="CD003256-sec-0101"> <h6 class="title">Liposomal doxorubicin versus conservative management (defined as bleomycin plus vinblastine, or vincristine or single‐agent antiretroviral therapy alone) </h6> <p>In <a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a>, all 29 participants in the study were T1. There were 20 in the liposomal doxorubicin group and 9 in the group receiving conservative management. Seventeen out of 20 patients in the liposomal doxorubicin group received antiretroviral therapy, which was most likely single agent, as only a subset of these patients (2 out of the 17) received a combination of PI plus nucleosides. Of the nine patients in the group receiving conservative management, four had bleomycin and vinblastine or vincristine and five did not receive chemotherapy. Two out of the five that did not receive chemotherapy received interferon. Five of the nine patients in this group had antiretroviral therapy alone which appears to have been single agent therapy, although details on specific antiretrovirals used are lacking. </p> <p>The outcomes reported were:</p> <section id="CD003256-sec-0102"> <p><b>Mortality</b></p> <p>There were 18 deaths out of 20 in the stealth liposomal doxorubicin group, while all nine patients receiving conservative management died(RR 0.93; 95% CI 0.75 to 1.15) (<a href="./references#CD003256-fig-0021" title="">Analysis 9.1</a>). </p> </section> <section id="CD003256-sec-0103"> <p><b>Adverse events</b></p> <p>All 20 patients in the liposomal doxorubicin group were reported to have adverse events (grade 1 to 4). </p> </section> <section id="CD003256-sec-0104"> <p><b>Time to mortality (time after diagnosis of pulmonary Kaposi's sarcoma to death)</b></p> <p>The mean survival time was 11.81 months (standard deviation (SD) 1.78) in the liposomal doxorubicin group and 4.44 months (SD 1.68) in the conservative management group. (Cox regression p&lt;0.01). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003256-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003256-sec-0105"></div> <section id="CD003256-sec-0106"> <h3 class="title" id="CD003256-sec-0106">Summary of main results</h3> <p>We included six randomised trials involving 610 HIV‐infected adults with severe Kaposi's sarcoma (<a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a>; <a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a>; <a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a>; <a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a>; <a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a>; <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>), and three observational studies involving a total of 182 HIV‐infected adults with severe Kaposi's sarcoma (<a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a>; <a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a>; <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a>). None of the included studies with the same study design compared similar interventions. Of the nine included studies, seven included patients with a mix of mild to moderate (T0) and severe (T1) Kaposi's sarcoma. However, this review was restricted to severe disease only, therefore we only extracted data for T1 Kaposi's sarcoma participants. There was no universal consensus in included studies on the severity of disease that is truly requiring of chemotherapy. </p> <p>In the previous version of this Cochrane review (<a href="./references#CD003256-bbs2-0075" title="DedicoatM , VaithilingumM , NewtonRR . Treatment of Kaposis sarcoma in HIV‐1 infected individuals with emphasis on resource poor settings. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD003256] ">Dedicoat 2003</a>), two large randomised trials (total of 499 T0 and T1 Kaposi's sarcoma patients) were pooled: <a href="./references#CD003256-bbs2-0034" title="NorthfeltDW , DezubeBJ , ThommesJA , MillerBJ , FischlMA , Freidman‐KienA , et al. Pegylated liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS related Kaposi's sarcoma: results of a randomised phase III clinical trial. Journal of Clinical Oncology1998;16(7):2445‐51. ">Northfelt 1998</a>, comparing pegylated liposomal doxorubicin (PLD) to doxorubicin, bleomycin and vincristine (ABV), and <a href="./references#CD003256-bbs2-0045" title="StewartS , JablonowskiH , GoebelFD , ArastehK , SpittleM , RiosA , et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1998;16(2):683‐91. ">Stewart 1998</a>, comparing PLD to bleomycin and vincristine. However, we excluded these studies from our update of the review because the results were not available according to Kaposi's sarcoma stage. The pooled analysis showed similar mortality and adverse events in both arms, but clinical response, which included complete and partial response, favoured PLD. </p> <p>Of the trials comparing highly active antiretroviral therapy (HAART) plus chemotherapy to HAART alone for patients with T1 Kaposi's sarcoma, only <a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a>, comparing HAART plus ABV to HAART alone, showed a significant reduction in disease progression in the HAART plus ABV group. There also appeared to be a reduction in mortality and adverse events but these were not statistically significant. It should be noted that the sickest patients requiring urgent chemotherapy were excluded from this trial, so it is possible that this is an underestimate of the reduction in morbidity and possibly mortality associated with ABV when added to HAART. Another trial involving 10 patients and comparing HAART plus pegylated liposomal doxorubicin to HAART alone did not show any significant benefit in clinical response, but was of very small sample size (<a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a>). The <a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a> cohort included patients on HAART alone and also on HAART plus liposomal anthracycline but was not designed to compare these two groups. A subset of this cohort was presented in <a href="./references#CD003256-bbs2-0028" title="LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Letang 2013</a> which showed a non‐statistically significant reduction in Kaposi's sarcoma immune reconstitution inflammatory syndrome (IRIS) in patients that received HAART plus liposomal anthracyclines, but no difference in mortality between groups. All T1 Kaposi's sarcoma patients in this study were meant to receive chemotherapy as per protocol; patients who received HAART alone were therefore exceptions. </p> <p>Of the studies comparing HAART plus chemotherapy to HAART plus a different chemotherapy regimen, <a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a>, involving 49 T1 patients and comparing paclitaxel versus pegylated liposomal doxorubicin (PLD) in patients on HAART, did not demonstrate a difference between the two groups in disease progression or clinical response. Another trial involving 46 T1 disease patients, comparing pegylated liposomal doxorubicin to liposomal daunorubicin, showed no participants with progressive Kaposi's sarcoma disease in either group (<a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a>). We did not identify any randomised controlled studies from the modern HAART era that directly compared HAART plus liposomal anthracyclines to HAART plus ABV. In addition, we did not identify any studies that evaluated timing of chemotherapy, i.e. whether there was a benefit to starting chemotherapy prior to HAART as compared to simultaneous administration. </p> <p>Other studies compared different chemotherapy regimens in patients from the pre‐HAART era: <a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a>, involving 227 patients, compared liposomal daunorubicin to ABV and showed no significant difference with the use of liposomal daunorubicin compared to ABV in disease progression and overall response rate. The exclusion of the <a href="./references#CD003256-bbs2-0034" title="NorthfeltDW , DezubeBJ , ThommesJA , MillerBJ , FischlMA , Freidman‐KienA , et al. Pegylated liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS related Kaposi's sarcoma: results of a randomised phase III clinical trial. Journal of Clinical Oncology1998;16(7):2445‐51. ">Northfelt 1998</a> and <a href="./references#CD003256-bbs2-0045" title="StewartS , JablonowskiH , GoebelFD , ArastehK , SpittleM , RiosA , et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1998;16(2):683‐91. ">Stewart 1998</a> studies is discussed above. <a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a>, a trial involving 178 patients comparing oral etoposide versus ABV in patients not on antiretroviral therapy, demonstrated no significant difference in mortality between groups. <a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a>, a prospective non‐randomised trial (24 patients) comparing bleomycin to ABV in the pre‐HAART era, demonstrated a higher mean survival time and no reported adverse events in the ABV group. However, there was no significant difference in disease progression between the two groups. An additional retrospective study, involving 29 patients in the pre‐HAART era, showed a non‐statistically significant overall mortality benefit for liposomal doxorubicin compared to conservative management consisting of either bleomycin plus vinblastine, vincristine or single‐agent antiretroviral therapy alone (<a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a>). Liposomal doxorubicin also showed a significant survival time benefit. </p> </section> <section id="CD003256-sec-0107"> <h3 class="title" id="CD003256-sec-0107">Overall completeness and applicability of evidence</h3> <p>We included all studies that met the inclusion criteria for this review. The trials included HIV‐infected adults with severe or progressive Kaposi's sarcoma, as defined by AIDS Clinical Trial Group T1 or progressive disease. We identified no studies on the relative timing of HAART in relationship to chemotherapy. Most of the included studies were not designed or powered specifically to address outcomes for patients with severe or progressive Kaposi's sarcoma. We were not able to do a subgroup analysis to assess if there were particular subgroups within the population of patients with T1 KS that would benefit more or less from chemotherapy. Some of the outcomes addressed in the studies could not be reported here because they were not presented according to disease severity (i.e. mixed T0 and T1). The studies were conducted in both resource‐poor and rich settings. Therefore, the findings from this review are applicable to various settings, but identified major gaps in the literature as above. </p> </section> <section id="CD003256-sec-0108"> <h3 class="title" id="CD003256-sec-0108">Quality of the evidence</h3> <p>We assessed the quality of evidence using the GRADE approach and presented this in the 'Summary of findings' tables (<a href="./full#CD003256-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD003256-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD003256-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD003256-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD003256-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD003256-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD003256-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD003256-tbl-0008">summary of findings Table 8</a>; <a href="./full#CD003256-tbl-0009">summary of findings Table 9</a>). The overall quality of evidence in this review can be described as moderate. We downgraded the quality of evidence due to the small size of many of the included studies and the low numbers of events. </p> </section> <section id="CD003256-sec-0109"> <h3 class="title" id="CD003256-sec-0109">Potential biases in the review process</h3> <p>We conducted a comprehensive search of databases and conference proceedings and we contacted experts in the field to ensure that all relevant completed, unpublished or ongoing studies were identified. There was no language restriction. We also contacted study authors where possible for clarification where this was required and for unpublished data where necessary. Unpublished data was included in the review. We minimised potential bias in the conduct of this review by having at least two authors independently scan through the search output, extract data and assess the methodological quality of each study. </p> </section> <section id="CD003256-sec-0110"> <h3 class="title" id="CD003256-sec-0110">Agreements and disagreements with other studies or reviews</h3> <p>The only data from comparison of liposomal anthracyclines with ABV come from the pre‐HAART era; in contrast to the prior Cochrane review <a href="./references#CD003256-bbs2-0075" title="DedicoatM , VaithilingumM , NewtonRR . Treatment of Kaposis sarcoma in HIV‐1 infected individuals with emphasis on resource poor settings. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD003256] ">Dedicoat 2003</a>, the single study in this comparison included here did not show a definitive advantage from liposomal anthracyclines over ABV. However, two large randomised controlled trials on this topic had to be excluded due to their mix of mild and severe Kaposi's sarcoma patients. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003256-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD003256-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003256-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003256-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 1 Mortality." data-id="CD003256-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 2 Progressive disease." data-id="CD003256-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 2 Progressive disease.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 3 Clinical response." data-id="CD003256-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 3 Clinical response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 4 Adverse events." data-id="CD003256-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 HAART + ABV versus HAART alone (RCT), Outcome 4 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 HAART + pegylated liposomal doxorubicin versus HAART alone (RCT), Outcome 1 Clinical response." data-id="CD003256-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 HAART + pegylated liposomal doxorubicin versus HAART alone (RCT), Outcome 1 Clinical response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 HAART + liposomal anthracycline versus HAART alone (cohort study), Outcome 1 Mortality." data-id="CD003256-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 HAART + liposomal anthracycline versus HAART alone (cohort study), Outcome 1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 HAART + liposomal anthracycline versus HAART alone (cohort study), Outcome 2 KS IRIS." data-id="CD003256-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 HAART + liposomal anthracycline versus HAART alone (cohort study), Outcome 2 KS IRIS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT), Outcome 1 Progression of KS." data-id="CD003256-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT), Outcome 1 Progression of KS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT), Outcome 2 Clinical response." data-id="CD003256-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT), Outcome 2 Clinical response. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 HAART + pegylated liposomal doxorubicin versus HAART + liposomal daunorubicin (RCT), Outcome 1 Progression of KS." data-id="CD003256-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 HAART + pegylated liposomal doxorubicin versus HAART + liposomal daunorubicin (RCT), Outcome 1 Progression of KS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Liposomal daunorubicin versus ABV (RCT), Outcome 1 Progression of KS." data-id="CD003256-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Liposomal daunorubicin versus ABV (RCT), Outcome 1 Progression of KS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Liposomal daunorubicin versus ABV (RCT), Outcome 2 Clinical response." data-id="CD003256-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Liposomal daunorubicin versus ABV (RCT), Outcome 2 Clinical response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Liposomal daunorubicin versus ABV (RCT), Outcome 3 Adverse events." data-id="CD003256-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Liposomal daunorubicin versus ABV (RCT), Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Oral etoposide versus ABV (RCT), Outcome 1 Mortality." data-id="CD003256-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Oral etoposide versus ABV (RCT), Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Bleomycin versus ABV (non‐RCT), Outcome 1 Mortality." data-id="CD003256-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Bleomycin versus ABV (non‐RCT), Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Bleomycin versus ABV (non‐RCT), Outcome 2 Clinical response." data-id="CD003256-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Bleomycin versus ABV (non‐RCT), Outcome 2 Clinical response.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Bleomycin versus ABV (non‐RCT), Outcome 3 Adverse events." data-id="CD003256-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Bleomycin versus ABV (non‐RCT), Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003256-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/urn:x-wiley:14651858:media:CD003256:CD003256-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_t/tCD003256-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Liposomal doxorubicin versus conservative management (non‐RCT), Outcome 1 Mortality." data-id="CD003256-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Liposomal doxorubicin versus conservative management (non‐RCT), Outcome 1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/media/CDSR/CD003256/image_n/nCD003256-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003256-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HAART + ABV compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HAART + ABV compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0008" title="BihlF , MosamA , HenryLN , ChisholmJV3rd , DollardS , GumbiP , et al. Kaposi's sarcoma‐associated herpesvirus‐specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C‐infected individuals with Kaposi's sarcoma. AIDS (London, England)2007;21(10):1245‐52. [PUBMED: 17545700] MosamA , ShaikF , UldrickTS , EsterhuizenT , FriedlandGH , ScaddenDT , et al. A randomized controlled trial of highly active antiretroviral therapy versus highly active antiretroviral therapy and chemotherapy in therapy‐naive patients with HIV‐associated Kaposi sarcoma in South Africa. Journal of Acquired Immune Deficiency Syndromes2012;60(2):150‐7. [PUBMED: 22395672] ">Mosam 2012</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> Durban, South Africa<br/> <b>Intervention:</b> HAART + ABV<br/> <b>Comparison:</b> HAART alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + ABV</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>240 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> <br/> (108 to 451) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.92</b> <br/> (0.45 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progressive disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> <br/> (2 to 150) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.1</b> <br/> (0.01 to 0.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>80 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> <br/> (51 to 498) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2</b> <br/> (0.64 to 6.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ partial response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>280 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>479 per 1000</b> <br/> (283 to 815) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.71</b> <br/> (1.01 to 2.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ stable disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (0 to 158) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.06</b> <br/> (0 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ overall response (complete and partial)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>641 per 1000</b> <br/> (418 to 979) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.78</b> <br/> (1.16 to 2.72) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> <br/> Follow‐up: mean 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>520 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>458 per 1000</b> <br/> (307 to 686) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/> (0.59 to 1.32) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ABV:</b> doxorubicin, bleomycin and vincristine; <b>CI:</b> confidence interval; <b>HAART:</b> highly active antiretroviral therapy; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">HAART + ABV compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003256-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">HAART + pegylated liposomal doxorubicin compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HAART + pegylated liposomal doxorubicin compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0007" title="Martin‐CarboneroL , BarriosA , SaballsP , SireraG , SantosJ , PalaciosR , et al. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma. AIDS (London, England)2004;18(12):1737‐40. [PUBMED: 15280789] ">Martin‐Carbonero 2004</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> Spain<br/> <b>Intervention:</b> HAART + PLD<br/> <b>Comparison:</b> HAART alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + PLD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 9</b> <br/> (0.61 to 133.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>HAART:</b> highly active antiretroviral therapy; <b>PLD:</b> pegylated liposomal doxorubicin; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">HAART + pegylated liposomal doxorubicin compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003256-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">HAART + liposomal anthracycline compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HAART + liposomal anthracycline compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0001" title="BowerM , Dalla PriaA , CoyleC , AndrewsE , TittleV , DhootS , et al. Prospective stage‐stratified approach to AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology2014;32(5):409‐14. BowerM ,  WeirJ ,  FrancisN ,  Newsom‐DavisT ,  PowlesS ,  CrookT ,  etal . The effect of HAART in 254 consecutive patients with AIDS‐related Kaposi's sarcoma. AIDS2009;23(13):1701‐6. LetangE , LewisJJ , BowerM , MosamA , BorokM , CampbellTB , et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma: higher incidence and mortality in Africa than in the UK. AIDS2013;27(10):1603‐13. [PUBMED: 23462220] ">Bower 2009</a><b>) ‐ cohort study</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> United Kingdom<br/> <b>Intervention:</b> HAART + liposomal anthracycline<br/> <b>Comparison:</b> HAART alone </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART alone</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + liposomal anthracycline</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>62 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/> (22 to 274) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.23</b> <br/> (0.35 to 4.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Kaposi's sarcoma IRIS</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>125 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b> <br/> (20 to 194) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.49</b> <br/> (0.16 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>IRIS:</b> immune reconstitution inflammatory syndrome; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">HAART + liposomal anthracycline compared to HAART alone for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003256-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">HAART + paclitaxel compared to HAART + pegylated liposomal doxorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HAART + paclitaxel compared to HAART + PLD for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0002" title="CianfroccaM , LeeS , VonRoennJ , TulpuleA , DezubeBJ , AboulafiaDM , et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus‐associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. Cancer2010;116(16):3969‐77. [PUBMED: 20564162] ">Cianfrocca 2010</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> USA<br/> <b>Intervention:</b> HAART + paclitaxel<br/> <b>Comparison:</b> HAART + PLD </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + PLD</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + paclitaxel</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression of Kaposi's sarcoma</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>42 per 1000</b> <br/> (3 to 629) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/> (0.07 to 15.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> <br/> (8 to 860) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.08</b> <br/> (0.2 to 21.5) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ partial response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>360 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b> <br/> (180 to 781) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.04</b> <br/> (0.5 to 2.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ stable disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>400 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>248 per 1000</b> <br/> (108 to 580) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.63</b> <br/> (0.27 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>HAART:</b> highly active antiretroviral therapy; <b>PLD:</b> pegylated liposomal doxorubicin; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">HAART + paclitaxel compared to HAART + pegylated liposomal doxorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003256-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">HAART + pegylated liposomal doxorubicin compared to HAART + liposomal daunorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>HAART + pegylated liposomal doxorubicin compared to HAART + liposomal daunorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0003" title="CooleyT , HenryD , TondaM , SunS , O'ConnellM , RackoffW . A randomized, double‐blind study of pegylated liposomal doxorubicin for the treatment of AIDS‐related Kaposi's sarcoma. The Oncologist2007;12(1):114‐23. [PUBMED: 17227906] ">Cooley 2007</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> USA<br/> <b>Intervention:</b> HAART + pegylated liposomal doxorubicin<br/> <b>Comparison:</b> HAART + liposomal daunorubicin </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + liposomal daunorubicin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> HAART + PLD</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression of Kaposi's sarcoma</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>HAART:</b> highly active antiretroviral therapy; <b>PLD:</b> pegylated liposomal doxorubicin; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">HAART + pegylated liposomal doxorubicin compared to HAART + liposomal daunorubicin for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003256-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Liposomal daunorubicin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Liposomal daunorubicin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0004" title="GillPS , WernzJ , ScaddenDT , CohenP , MukwayaGM , vonRoennJH , et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS‐related Kaposi's sarcoma. Journal of Clinical Oncology1996;14(8):2353‐64. [PUBMED: 8708728] ">Gill 1996</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> USA<br/> <b>Intervention:</b> liposomal daunorubicin<br/> <b>Comparison:</b> ABV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ABV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Liposomal daunorubicin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Progression of Kaposi's sarcoma</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>99 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>77 per 1000</b> <br/> (34 to 180) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> <br/> (0.34 to 1.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>9 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> <br/> (3 to 245) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 2.87</b> <br/> (0.3 to 27.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ partial response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>270 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>224 per 1000</b> <br/> (143 to 354) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.83</b> <br/> (0.53 to 1.31) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ overall response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>279 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>251 per 1000</b> <br/> (162 to 385) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.9</b> <br/> (0.58 to 1.38) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ stable disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>577 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>623 per 1000</b> <br/> (502 to 767) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.87 to 1.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>964 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>974 per 1000</b> <br/> (925 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.01</b> <br/> (0.96 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>227<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ABV:</b> doxorubicin, bleomycin and vincristine; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Liposomal daunorubicin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003256-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Oral etoposide compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral etoposide compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0009" title="OlwenyCL , BorokM , GudzaI , ClinchJ , CheangM , KiireCF , et al. Treatment of AIDS‐associated Kaposi’s sarcoma in Zimbabwe: results of a randomized quality of life focused clinical trial. International Journal of Cancer2005;113:632‐9. ">Olweny 2005</a><b>) ‐ RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> Zimbabwe<br/> <b>Intervention:</b> oral etoposide<br/> <b>Comparison:</b> ABV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ABV </b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Oral etoposide</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>864 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>933 per 1000</b> <br/> (846 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.98 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ABV:</b> doxorubicin, bleomycin and vincristine; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were few events with wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Oral etoposide compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003256-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Bleomycin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Bleomycin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0006" title="HernandezDE ,  PerezJR . Systemic treatment modalities in the management of AIDS‐related Kaposi's sarcoma. Journal of the European Academy of Dermatology and Venereology1997;9:44‐9. ">Hernandez 1997</a><b>) ‐ non‐RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> Venezuela<br/> <b>Intervention:</b> bleomycin<br/> <b>Comparison:</b> ABV </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> ABV</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Bleomycin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>917 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>999 per 1000</b> <br/> (797 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.09</b> <br/> (0.87 to 1.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ complete response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ partial response</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>333 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> <br/> (3 to 620) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.11</b> <br/> (0.01 to 1.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ stable disease</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>587 per 1000</b> <br/> (313 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.88</b> <br/> (0.47 to 1.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical response ‐ progression</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 11</b> <br/> (0.67 to 179.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 11</b> <br/> (0.67 to 179.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>ABV:</b> doxorubicin, bleomycin and vincristine; <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events with very wide confidence intervals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Bleomycin compared to ABV for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003256-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Liposomal doxorubicin compared to conservative management for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Liposomal doxorubicin compared to bleomycin + vinblastine, vincristine or single‐agent antiretroviral therapy alone (conservative management) for the treatment of severe Kaposi's sarcoma in HIV‐infected adults (</b><a href="./references#CD003256-bbs2-0005" title="GrünaugM ,  BognerJR ,  LochO ,  GoebelFD . Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. European Journal of Medical Research1998;21(3):13‐9. ">Grünaug 1998</a><b>) ‐ non‐RCT</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐infected adults with severe (T1) Kaposi's sarcoma<br/> <b>Settings:</b> Germany<br/> <b>Intervention:</b> liposomal doxorubicin<br/> <b>Comparison:</b> conservative management </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Liposomal doxorubicin</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Conservative management</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mortality</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>930 per 1000</b> <br/> (750 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.93</b> <br/> (0.75 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>There were very few events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Liposomal doxorubicin compared to conservative management for the treatment of severe Kaposi's sarcoma in HIV‐infected adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003256-tbl-0010"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table 1. Cochrane CENTRAL search strategy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Search</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [Sarcoma, Kaposi] explode all trees</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>kaposi or karposi or KS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [Herpesvirus 8, Human] explode all trees</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hhv‐8 or hhv8 or KSHV or " human herpes virus 8" or "human herpesvirus 8"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#1 or #2 or #3 or #4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [HIV Infections] explode all trees</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [HIV] explode all trees</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>hiv or hiv‐1* or hiv‐2* or hiv1 or hiv2 or HIV INFECT* or HUMAN IMMUNODEFICIENCY VIRUS or HUMAN IMMUNEDEFICIENCY VIRUS or HUMAN IMMUNE‐DEFICIENCY VIRUS or HUMAN IMMUNO‐DEFICIENCY VIRUS or HUMAN IMMUN* DEFICIENCY VIRUS or ACQUIRED IMMUNODEFICIENCY SYNDROME or ACQUIRED IMMUNEDEFICIENCY SYNDROME or ACQUIRED IMMUNO‐DEFICIENCY SYNDROME or ACQUIRED IMMUNE‐DEFICIENCY SYNDROME or ACQUIRED IMMUN* DEFICIENCY SYNDROME </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [Lymphoma, AIDS‐Related] this term only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MeSH descriptor: [Sexually Transmitted Diseases, Viral] this term only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#6 or #7 or #8 or #9 or #10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#5 and #11 from 1980 to 2012, in Trials (Word variations have been searched)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table 1. Cochrane CENTRAL search strategy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003256-tbl-0011"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Table 2. PubMed search strategy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Search</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Query</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search ((#1 AND #2 AND #10)) AND ("1980/01/01"[Date ‐ Publication] : "2012/11/0"[Date ‐ Publication]) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (#1 AND #2 AND #10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (#3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search ((observational[tiab] AND (study[tiab] OR studies[tiab]))</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (evaluation studies as topic[mh:noexp] OR (evaluation[tiab] AND (study[tiab] OR studies[tiab])) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (cross‐sectional studies[mh] OR cross section*[tiab])</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (case control studies[mh] OR case control[tiab])</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search ((follow up[tiab] OR prospective[tiab] OR longitudinal[tiab] OR retrospective[tiab]) AND (study[tiab] OR studies[tiab])) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (cohort studies[mh] OR cohort[tiab] OR cohorts[tiab])</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (randomised controlled trial [pt] OR controlled clinical trial [pt] OR randomised [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh]) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search sarcoma, kaposi[mh] OR kaposi*[tiab] OR karposi*[tiab] OR KS[tiab] OR herpesvirus 8, human[mh] OR human herpes virus 8[tiab] OR human herpesvirus 8[tiab] OR hhv‐8[tiab] OR hhv8[tiab] OR KSHV[tiab] </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Search (HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tiab] OR hiv‐1*[tiab] OR hiv‐2*[tiab] OR hiv1[tiab] OR hiv2[tiab] OR hiv infect*[tiab] OR human immunodeficiency virus[tiab] OR human immunedeficiency virus[tiab] OR human immuno‐deficiency virus[tiab] OR human immune‐deficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR acquired immuno‐deficiency syndrome[tiab] OR acquired immune‐deficiency syndrome[tiab] OR ((acquired immun*[tiab]) AND (deficiency syndrome[tiab])) OR "sexually transmitted diseases, Viral"[MeSH:NoExp]) </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Table 2. PubMed search strategy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003256-tbl-0012"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Table 3. EMBASE search strategy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Query</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#1 AND #13 AND #14 AND [embase]/lim AND [1‐1‐1980]/sd NOT [26‐11‐2012]/sd</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#1 AND #13 AND #14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#14</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'kaposi sarcoma'/exp OR 'kaposi sarcoma' OR 'human herpesvirus 8'/exp OR 'human herpesvirus 8' OR kaposi*:ab,ti OR karposi*:ab,ti OR ks:ab,ti OR 'human herpes virus 8':ab,ti OR 'hhv‐8':ab,ti OR hhv8:ab,ti OR kshv:ab,ti </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#13</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#7 OR #8 OR #9 OR #10 OR #11 OR #12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'observational study'/exp OR (observational NEXT/1 (study OR studies)):ab,ti</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'evaluation'/exp OR (evaluation NEXT/1 (study OR studies)):ab,ti</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'cross‐sectional study'/exp OR (cross NEXT/1 section*):ab,ti</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'case control study'/exp OR 'case control':ab,ti</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'cohort analysis'/exp OR 'cohort analysis' OR 'longitudinal study'/exp OR 'longitudinal study' OR 'prospective study'/exp OR 'prospective study' OR 'follow up'/exp OR 'follow up' OR cohort*:ab,ti OR 'longitudinal studies':ab,ti OR 'prospective studies':ab,ti </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#2 NOT #6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#3 NOT #5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>#3 AND #4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'human'/de</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'animal'/de OR 'nonhuman'/de OR 'animal experiment'/de</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'randomised controlled trial'/de OR 'randomised controlled trial (topic)'/exp OR random*:ab,ti OR trial:ti OR allocat*:ab,ti OR placebo*:ab,ti OR 'crossover procedure'/de OR 'double‐blind procedure'/de OR 'single‐blind procedure'/de OR (doubl* NEAR/3 blind*):ab,ti OR (singl* NEAR/3 blind*):ab,ti OR crossover*:ab,ti OR cross+over*:ab,ti OR (cross NEXT/1 over*):ab,ti </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>#1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>'human immunodeficiency virus infection'/exp OR 'human immunodeficiency virus'/exp OR 'human immunodeficiency virus':ab,ti OR 'human immuno+deficiency virus':ab,ti OR 'human immunedeficiency virus':ab,ti OR 'human immune+deficiency virus':ab,ti OR hiv:ab,ti OR 'hiv‐1':ab,ti OR 'hiv‐2':ab,ti OR 'acquired immunodeficiency syndrome':ab,ti OR 'acquired immuno+deficiency syndrome':ab,ti OR 'acquired immunedeficiency syndrome':ab,ti OR 'acquired immune+deficiency syndrome':ab,ti </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Table 3. EMBASE search strategy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/full#CD003256-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003256-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">HAART + ABV versus HAART alone (RCT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Progressive disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.1 [0.01, 0.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Complete response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.64, 6.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Partial response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.01, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Stable disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.00, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Overall response (complete and partial)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.78 [1.16, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.59, 1.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">HAART + ABV versus HAART alone (RCT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003256-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">HAART + pegylated liposomal doxorubicin versus HAART alone (RCT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.0 [0.61, 133.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">HAART + pegylated liposomal doxorubicin versus HAART alone (RCT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003256-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">HAART + liposomal anthracycline versus HAART alone (cohort study)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.35, 4.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 KS IRIS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.16, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">HAART + liposomal anthracycline versus HAART alone (cohort study)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003256-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Progression of KS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.07, 15.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Complete response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [0.20, 21.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Partial response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.50, 2.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Stable disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.27, 1.45]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003256-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">HAART + pegylated liposomal doxorubicin versus HAART + liposomal daunorubicin (RCT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Progression of KS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">HAART + pegylated liposomal doxorubicin versus HAART + liposomal daunorubicin (RCT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003256-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Liposomal daunorubicin versus ABV (RCT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Progression of KS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.34, 1.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Complete response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.87 [0.30, 27.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Partial response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.53, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Overall response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.58, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Stable disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.87, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>227</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.96, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Liposomal daunorubicin versus ABV (RCT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003256-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Oral etoposide versus ABV (RCT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.98, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Oral etoposide versus ABV (RCT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003256-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Bleomycin versus ABV (non‐RCT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.87, 1.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical response <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Complete response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Partial response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [0.01, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Stable disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.47, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.0 [0.67, 179.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.0 [0.67, 179.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Bleomycin versus ABV (non‐RCT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003256-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Liposomal doxorubicin versus conservative management (non‐RCT)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.75, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Liposomal doxorubicin versus conservative management (non‐RCT)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003256.pub2/references#CD003256-tbl-0021">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003256.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003256-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003256-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD003256-note-0001">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003256\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003256\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003256\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003256\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003256\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003256.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003256.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003256.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003256.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003256.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726859163"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003256.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726859167"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003256.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9df03a93f480',t:'MTc0MDcyNjg1OS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 